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 Cancer has become a major threat to people’s lives in the world. The 
development of new technologies for its early detection and diagnosis can significantly 
reduce its mortality and improve the life quality of patients. Nanotechnology is currently 
under intense research for cancer detection, diagnosis and treatment. In particular, 
nanometer-sized quantum dots (QDs) are a new class of nanosized probes for cancer 
detection and imaging because of their novel optical, electronic, and structural properties. 
Here we have designed and developed a class of biocompatible hyaluronic acid polymer 
coated QDs for CD44+ cancer targeting and optical imaging. The coated QDs have 
excellent water solubility, biocompatibility, stability, as well as the ability to target the 
CD44 receptor on tumor cells.  Furthermore, we have developed a class of multi-
modality imaging probes by conjugating the hyaluronic polymer to gadolinium and 
copper chelating agents (such as DTPA and DOTA). These multi-modality imaging 
probes provide the ability for fluorescence imaging, magnetic resonance imaging (MRI), 
and positron emission tomography (PET) imaging. The results show that this multimodal 
approach can combine the advantages of different imaging modalities and can lead to 
improved tumor detection and identification. These new imaging probes are expected to 








Cancer by definition is the uncontrolled growth of cells that can invade and 
spread to distant sites of the body. Cancer can have serious health consequences, and is a 
leading cause of death all over the world. Cancer affects everyone and brings a 
tremendous burden to patients, families and societies. Cancer is a leading cause of death 
worldwide, and accounts for 8.2 million deaths in 2012. From the 2014 world cancer 
report, cancers figure among the leading causes of morbidity and mortality worldwide, 
with about 14 million new cases and 8.2 million cancer related deaths in 2012 [1]. It is 
expected that annual cancer cases will rise from 14 million in 2012 to 22 million within 
the next two decades. As Dr. Varmus mentioned, ‘Indeed, the age-adjusted mortality rate 
for cancer is about the same in the 21st century as it was 50 years ago, whereas the death 
rates for cardiac, cerebrovascular, and infectious diseases have declined by about two-
thirds.’[18] Early detection, accurate diagnosis, and effective treatment help increase 
cancer survival rates and reduce suffering. Among all the cancers, lung, liver, stomach, 
colorectal and breast cancers cause the most cancer deaths each year, as shown in Figure 
1.1. Research has vastly expanded our knowledge of cancer and cancer biology, 
particularly with new insights into the molecular mechanism of the disease[19, 20]. 
Although people have made a lot of progress in the treatment of cancer, substantial 
hurdles still remain because of its complexity nature. Because of these research efforts 
and recent advances in diagnostic technologies, there is an opportunity to bring the idea 
of ‘personalized medicine’ to reality. As WHO pointed out, 30% of cancers could be 
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prevented and early detection of cancer will greatly improve the likelihood for successful 
treatment.  
Nanotechnology is a multidisciplinary field and it covers a broad diversification 
range from engineering, biology, physics and chemistry [21]. Formal definition of nano-
technological devices typically feature the requirements that the device itself or its 
essential components be man-made, and in the 1–100 nm range which is from a few 
atoms to subcellular size in at least one dimension. Two main fields of nanotechnology 
are nanovectors for the administration of targeted therapeutic and imaging moieties and 
the precise patterning of surfaces. Cancer-related examples of nanotechnologies include 
injectable drug delivery nanovectors such as liposomes for the therapy of breast cancer, 
biologically targeted, nanosized contrast agents for intraoperative imaging and novel, 
nanoparticle-based methods for high-specificity detection of DNA and protein. If 
properly combined with cancer research, nanotechnology provides a lot of opportunities 
to meet the challenges in cancer. 
 
Figure 1.1. Among all the cancers, Lung, liver, stomach, colorectal and breast cancers 





Figure 1.2. Nanometer scale comparison showing the nanoparticles size (from Peter 
R. Wich Research Lab) 
 
Multifunctionality is the fundamental advantage of nanovectors for the cancer-
specific delivery of therapeutic and imaging agents. The size and multicomponent nature 
of many nanomaterials offer an excellent platform to combine different materials for 
various imaging modalities. Primary functionalities include the avoidance of biobarriers 
and biomarker-based targeting, and the reporting of therapeutic efficacy. The dilemma of 
imaging modality selection in the clinic is that each modality has its own unique 
advantages and intrinsic limitations [22], such as insufficient sensitivity or low spatial 
resolution, so it remains difficult to extract accurate and reliable biomedical information 
solely based on single imaging modalities. Integrating the advantages of different 
imaging techniques is apparently an effective approach for improving the efficacy of 
clinical imaging diagnosis. Although the optical imaging techniques have shown 
potentials in extracting detailed biomedical information with high imaging sensitivities 
and low cost in imaging facilities, the assist of anatomical information is essentially 
required. Although not all imaging applications require multiple imaging modalities bind 
to a single probe, a multi-modality imaging probe has many advantages. A multi-modal 
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probe can guarantee the same pharmacokinetics and co-localization of different imaging 
modes. Also it avoid using multiple doses of imaging probes to bring a lot of pressure to 
the in vivo blood clearance [14].  
A combination of MRI and optical imaging techniques can achieve more accurate 
biomedical detection, in which the whole body MRI or optical imaging can be used to 
track the probe distribution in the body [22-24]. Although the body optical imaging is 
less powerful compared to MRI, fluorophores allow histological studies after whole body 
imaging where optical imaging provides great convenience.  
QDs are nanometer-sized crystals of semiconductor materials (typically 2-8 nm) 
that emit fluorescent light with great intensity and unparalleled signal stability. These 
attributes have found immediate use for monitoring individual molecules on cell surfaces 
in real time for extended periods, for sensitive detection of cancer in vivo, and for 
sensitive and specific characterization of viruses and cancer antigens in body fluids[2, 4, 
6, 25-33]. Compared with traditional organic dyes and fluorescent proteins, QDs are 
highly bright and resistant to photobleaching. Even importantly they have size, 
composition, and lattice strain tunable emission wavelength [4, 34-36]. However, great 
concern has been raised over the application of quantum dots in living cells and animals 
due to their chemical composition of toxic heavy metals like Cd. Some studies have 
indicated that the cytotoxicity of QDs strongly correlated with the stability and surface 
coatings of these nanoparticles[6, 31, 37, 38]. Besides, for biomedical applications, ideal 
QDs should not only have good water solubility, high stability, minimized cell toxicity, 
but also have abundant functional groups such as amine (–NH2) and carboxyl (–COOH) 
groups for further conjugation toward specific targeted imaging. 
A number of QDs surface coating methods have been used, which include silica 
coating [25, 38, 39], encapsulation with amphiphilic polymers (most commercial water-
soluble QDs) [40-42], and ligand replacement with hydrophilic ligands [27, 43, 44]. 
Silica shell coating and amphiphilic polymer encapsulation provide QDs with good 
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aqueous solubility and preserve high photoluminescence quantum yields. However, this 
approach is complex and usually results in large hydrodynamic diameters of 30–50 nm 
[27, 38], which are often much larger than the cellular receptors being labeled, and 
become a barrier for the widespread application of QDs in biomedical imaging. Due to 
the particularly strong affinity of sulfur for the metallic cations on the surface of QDs, 
mercaptopropionic acid (MPA) [27] and cysteine [43] are widely used as phase transfer 
reagents for QDs, owing to its simplicity, speed, and smaller size. Nevertheless, the 
colloidal stability is still limited due to the poor protection and drastic decrease in the 
quantum yields of the resulting water-soluble QDs. Thus, how to obtain water-soluble 
QDs with high quantum yield and high stability remains a great challenge. 
Another way to make QDs watersoluble is through multidentate polymer coating 
by ligand exchange, which usually produces compact QDs with high colloidal stability, 
with different combinations of polymer backbone, anchoring groups and pendant groups 
[44-54]. However, further bioconjugation is needed since there are not any recognition 
sites on common polymers, which will increase the size of QDs and make the experiment 
too complicated. Therefore, if one can realize specific targeting and good stability as well 
as biocompatibility through one surface modification step, it would be very convenient 
for the further biomedical application of QDs. 
At present, many people have used quantum dots to develop a lot of bimodal 
probes, such as PET or MRI. These methods can mainly be divided into three categories 
[14]. The first is through conjugates and other molecules such as Gd and Cu are attached 
to the QDs through surface chemistry. A typical approach is to attach chelators such as 
tetra-azacyclododecanetetra-acetic acid (DOTA) and diethylenetriaminepentaacetic acid 
(DTPA) to the surface of QDs to metalate PET- or MRI-active molecules Cu and Gd [55-
57]. The second method is through core-shell structure and other molecules are 
incorporated in an additional layer coating the QDs [58, 59]. The third method is by 
doping appropriate molecules such as Mn to the core of the QDs [22, 60]. 
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Hyaluronic acid (HA), which is a natural polysaccharide abundant in extracellular 
matrix, has been widely used in skin care [61, 62] and wound healing [63, 64] due to its 
intrinsic physicochemical and biological properties including great water retention ability 
and biocompatibility. HA is also reported to selectively bind with CD44 receptor, which 
is overexpressed in many cancers of epithelial origin [65] such as ovarian carcinoma [66] 
and breast adenocarcinoma [67]. Owing to these unique features, HA has been used for 
development of the targetable carriers to deliver the therapeutic agents such as drug 
delivery [68] and siRNA delivery [69-71] as well as imaging agents [72, 73]. 
Additionally, HA also contains derivable functional groups along its backbone. For 
instance, the carboxyl groups are good sites to be conjugated with thiol-containing 
cysteamine for QD surface binding. The hydroxyl groups can also act as good sites to 
conjugate DTPA, the Gd coupling unit for MRI imaging and conjugate DOTA, the Cu 
coupling unit for PET imaging [74, 75].  
1.2 Thesis goals 
This thesis aims to establish a facile and convenient method to obtain 
multimodality imaging probes based on QDs for the development of advanced functional 
nanometer scale tools for multimodality and targeted imaging of cancer. This goal is 
approached from three directions.  
First, an understanding of the physics of the optical and electronic properties of 
quantum dots, previous coating and bioconjugation methods for QDs and biomedical 
applications of QDs is summarized. This is performed by providing an exhaustive review 
of the properties and applications of quantum dots (Chapter 2).  
Second, a novel biocompatible Hyaluronic acid polymer was modified to coat the 
QDs and the colloidal properties of these nanocrystals were studied comprehensively. Its 
cellular toxicity and targeted imaging ability was also studied (Chapter 3).  
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Finally, the possibility of making multimodality QDs was tried by conjugating the 
HA cystamine polymer with DTPA and DOTA. HA-DTPA cysteamine polymer-coated 
QDs were conjugated with Gd for dual-modality MRI/optical imaging applications. 
Those QDs was used for MRI imaging and its longitudinal relaxation rate was calculated. 
HA-DOTA cystamine polymer was also synthesized and conjugate with Cu. The Cu 
content was determined by ICP-AES (Chapter 4).  
We expect the multi-modality imaging methods can be extended to 
SPECT/optical, MRI/PET/optical, CT/PET/SPECT imaging and other combinations for 








Quantum dots are nanometer-sized nanocrystals composed of semiconductor 
materials that have unique optical and electronic properties. The most important and 
useful feature of these particles is their size-dependent absorption and 
photoluminescence, which make them ideal for use in a number of biomedical 
applications. In this chapter, we will discuss the physical principles and properties of 
QDs. We will also describe the synthesis and coating methods of QDs. Finally, the 
relevant uses of QDs for biological applications will also be discussed. 
2.1 Semiconductor physics and semiconductor nanocrystals 
2.1.1 Semiconductor physics and nanocrystals 
Solid state physics and materials science broadly classify solids as conductors, 
semiconductors, or insulators, depending on the capacity of the materials to conduct 
electricity at room temperature. The difference between these materials arises from the 
bandgap energy (Eg), the energy difference between the highest occupied electronic 
energy level and the lowest unoccupied electronic energy level. The energy difference 
separating these bands is called the bandgap, a region of forbidden electronic energy 
within the solid. If an electron is excited, for example absorption of a photon whose 
energy is greater than the bandgap, or through thermal excitation, the electron is free to 
move in the solid upon application of an electric field, thus generating current. 
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Semiconductors have energy gaps that are small enough to allow room temperature 
conduction, but large enough that the magnitude of conduction can be largely controlled 
by a host of useful intrinsic and extrinsic factors, such as doping, the presence of a 
magnetic field, material strain, or incident light. 
When a photon of light with energy greater than Eg is illuminated on a 
semiconductor material, the electrons in the material can absorb the photon to transition 
to a higher electronic energy level, resulting in an excited state electron. As shown in 
Figure 2.1 B, an electron in the valence band absorbs a photon (green), exciting it to the 
conduction band, and leaving a positively charged hole in the valence band. The electron 
and hole quickly lose their excess kinetic energies through dissipation to lattice 
vibrations, settling at the band edges in a process called relaxation. The electron and hole 
can then recombine in a process that yields the emission of a single photon (red) with 
energy equal to the bandgap energy.  
 
Figure 2.1. (A). Diagram of electronic energy bands in solid-state materials showing 
the Bandgap (Eg) of semiconductor. Eg is the separation between the conduction and 
valence energy bands. (B). Electronic transitions in a semiconductor. (Figure from 
Andrew M. Smith.) 
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Many of the unique electronic and optical properties of QDs are the result of a 
phenomenon called  “quantum confinement” [76-78]. The first excited state of a 
semiconductor is the exciton state, in which an electron-hole pair is coulombically 
stabilized. The exciton state has a fundamental unit of length dictated by its Bohr radius, 
which can assume a value less than 1 nm diameter to over 100 nm, depending on the 
material. Therefore if the dimensions of the semiconductor crystal are on the nanometer 
scale, the electronic properties of a semiconductor can significantly differ from those of 
the bulk crystal. When a crystal is shrunk to a size similar to the Bohr diameter, the 
exciton becomes highly localized in space in the crystal. Similar to the classic example in 
quantum mechanics of a “particle in a box,”[79] the lowest energy state of the exciton 
(particle) will increase if the semiconductor nanocrystal (box) shrinks. This “quantum 
confinement effect” results in an increase in energy required to create the exciton and an 
increase in energy generated when the electron and hole recombine, i.e. an increase in the 
bandgap. This effect is illustrated by the characteristic blue-shift of the absorption and 
luminescence spectra for semiconductors nanocrystals near or smaller than the size of the 
exciton.  
The most important consequence of the quantum confinement effect is the size 
dependence of the bandgap for nanocrystalline semiconductors. By confining the exciton 
of a semiconductor, the bandgap may be tuned to a precise energy depending on the 
dimensionality and degree of confinement. 
2.1.2 Properties of Quantum Dots 
QDs are nanometer-sized crystals of semiconductor materials (typically 2-8 nm) 
that emit fluorescent light with great intensity and unparalleled signal stability. These 
attributes have found immediate use for monitoring individual molecules on cell surfaces 
in real time for extended periods, for sensitive detection of cancer in vivo, and for 
sensitive and specific characterization of viruses and cancer antigens in bodily fluids [2, 
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4, 6, 25-33]. Compared with traditional organic dyes and fluorescent proteins, QDs are 
highly bright and resistant to photobleaching. Even importantly they have size, 
composition, and lattice strain tunable emission wavelength [4, 34-36].  
The absorption and emission spectra of six different QDs was shown in Figure 
2.2. The black line shows the absorption of the QDs at 510nm emission. Size-tunable 
fluorescence properties and spectral range of the six QDs compare to CdSe core size were 
also plotted. All samples were excited at 365 nm with a UV light source [2]. 
Simultaneous excitation of multiple fluorescence colors spanning the entire visible range 
allows highly multiplexed staining of different disease biomarkers. 
 
 
Figure 2.2. Size-tunable fluorescence properties and spectral range of six QD 
dispersions. (from Mattoussi et al. [2]) 
 
Resistance to photobleaching is another important feature that is necessary for use 
in clinical applications. Unlike organic dyes that can easily photobleach upon exposure to 
light, the constant fluorescence intensity of QDs makes them ideal imaging and 
biosensing agents. As shown in Figure 2.3 [3], Nuclear antigens were labeled with QD 
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630–streptavidin (red), and microtubules were labeled with Alexa 488 conjugated to anti-
mouse IgG (green) simultaneously in a NIH/3T3 cell. The photos in bottom row showed 
microtubules that were labeled with QD 630–streptavidin (red), and nuclear antigens 
were stained green with Alexa 488 conjugated to anti-human IgG. The specimens were 
continuously illuminated for 3 min with light from a 100 W mercury lamp under a 100 
times 1.30 oil-immersion objective. Images at 0, 20, 60, 120, and 180 s are shown. 
Whereas labeling signals of Alexa 488 faded quickly and became undetectable within 2 
min, the signals of QD 630 showed no obvious change for the entire 3 min illumination 
period [3]. Quantitative analysis of changes in intensities of QD 608–streptavidin (stained 
microtubules) and Alexa 488–streptavidin (stained nuclear antigens) using specimens 
mounted with glycerol or antifade mounting medium were shown in Figure 2.3 B, QDs 
showed excellent photostability and resistance to photobleaching as compared to organic 
dyes, which make them ideal imaging and biosensing agents where consistent 
measurements are essential. 
 
Figure 2.3. Photostability comparison between QDs and Alexa 488. (from Wu et al. 
[3]) 
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2.2 Chemical synthesis and coating methods of Quantum Dots 
2.2.1 Chemical synthesis of QDs 
The synthesis of quantum confined semiconductor nanocrystals was first 
described in 1982 by Ekimov [80, 81], who grew nanocrystals and microcrystals of CuCl 
semiconductors in glass matrices. A major step toward the goal of monodisperse, 
colloidally dispersible, and highly fluorescent quantum dots was made by Bawendi and 
coworkers in 1993 with the introduction of nanocrystal synthesis in a high temperature 
coordinating solvent composed of trioctylphosphine (TOP) and trioctylphosphine oxide 
(TOPO) [82]. This novel demonstration of temporal separation of nucleation and growth 
was found to be crucial for the production of monodisperse samples, although size-
selective precipitations were still necessary to improve the size distribution. 
The next major development in colloidal quantum dot synthesis was the 
demonstration that the overgrowth of an insulating shell on the surface of a quantum dot 
tremendously enhances the photoluminescence efficiency. For example, Arnim Henglein 
and coworkers found that the addition of excess cations to alkaline aqueous solutions of 
semiconductor colloids (e.g. Cd2+ for CdS) resulted in large fluorescence enhancements 
[83]. This was hypothesized to be the results of surface defect passivation, and a similar 
trend was found for the addition of alkylamines [84]. It was also reported that when a 
wider bandgap material (ZnS) was grown on top of semiconductor nanocrystals (CdSe) in 
reverse micelles, the luminescence efficiency was tremendously enhanced [85]. Bawendi 
and coworkers improved this synthetic method and analyzed the luminescence 
dependence of the shell thickness from the perspective of interfacial strain [86].  
Up to now, considerable advances have been made in the chemical synthesis and 
preparation of high quality, monodispersed QDs [82, 87], especially with the use of 
organometallic and chelated cadmium precursors [88, 89], noncoordinating solvents [90], 
and inorganic passivating shells [86, 91]. These advances have led to the production of 
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nanoparticles with very narrow size distributions (fluorescence emission FWHM < 25 
nm) and high quantum yields (QY > 75%).  
While the resulting QDs have excellent physical and optical properties, the 
highest quality nanoparticles typically have hydrophobic surface ligands are often 
unsuited for use in biological environments. The production of biologically functional 
quantum dots has now become a multistep process involves three steps: 1. Synthesis of 
the nanocrystal core and growth of an inorganic shell (usually ZnS) to protect the optical 
properties of the quantum dot. 2. Coating of the QDs for phase transfer of the nanocrystal 
from organic liquid phase to aqueous solution. 3. Bioconjugation of biologically active 
molecules to the nanoparticle surface to render functionality, or linkage of biologically 
inert polymers to the nanoparticle to minimize biological activity.  
2.2.2 QDs coating methods 
To better make water-soluble QDs, a number of surface encapsulation and water 
solubilization strategies have been used to transfer QDs to aqueous solvents including 
direct ligand exchange of the hydrophobic surface ligands with hydrophilic small 
molecules, indirect surface encapsulation techniques using silica, lipids, block 
copolymers and low molecular weight amphiphilic polymers and multi-dentate polymers 
coating method. 
Direct ligand exchange 
For ligand exchange, a suspension of TOPO-coated quantum dots may be mixed 
with a solution containing an excess of a heterobifunctional ligand, which has one 
functional group that binds to the nanocrystal surface, usually a thiol group and another 
functional group that is hydrophilic. Thereby, hydrophobic TOPO ligands are displaced 
from the nanocrystal, as the new bifunctional ligand adsorbs to render water solubility. 
Thiol functional groups were found to strongly coordinate with the inorganic shell of the 
nanocrystal. Using this method, (CdSe)ZnS quantum dots have been coated with 
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mercaptoacetic acid [27] (3-mercaptopropyl) trimethoxysilane [25], and cysteine [43] 
,which contain basic thiol groups to bind to the zinc atoms on the nanocrystal surface, 
yielding quantum dots displaying carboxylic acids or silane monomers, respectively. 
These methods with simplicity and speed generate quantum dots of smaller size and 
useful for biological assays. Nevertheless, the colloidal stability is still limited due to the 
poor protection, and ligand exchange is commonly associated with decreased fluorescent 
efficiency and a propensity to aggregate and precipitate in biological buffers.  
Further advances have been made for this transfer strategy, using other functional 
groups to coordinate with the QD surface and ligand molecules capable of multivalent 
coordination to the surface [2, 44, 92-94], to improve the stability of the particles with 
different combinations of polymer backbone, anchoring groups and pendant groups [44-
54], which usually produces compact QDs with high colloidal stability. In addition, 
biocompatible molecules such as amino acids, proteins have also been used for direct 
ligand exchange and QD coatings [95, 96]. 
Surface encapsulation with amphiphilic polymers 
Another strategy for the transfer of QDs to aqueous environments involves the 
coating of the hydrophobic nanoparticles with amphiphilic polymers (most commercial 
water-soluble QDs) [40-42]. This method retains the native nonpolar coordinating ligands 
on the surface, and cover the hydrophobic nanocrystal with amphiphilic molecules, such 
as silica, lipids or polymers [6, 31, 97]. These methods yield water-soluble quantum dots 
that are stable for long periods of time due to a protective bilayer encapsulating the 
nanocrystal through hydrophobic interactions. Particles transferred using these techniques 
tend to have higher quantum yields than other particles, likely due to the protective layer 
of the hydrophobic segments of the polymer and the original surface ligands. These 
particles are also much more stable than ligand exchanged QDs, due to the multiple 
interactions between the polymer and the QD surface. One question of these strategies is 
a substantial increase in particle size. Nanoparticles are much larger when encapsulated 
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in amphiphiles compared to particles prepared using standard ligand exchange methods. 
This approach is complex and usually results in large hydrodynamic diameters of 30–50 
nm [27, 38], which are often much larger than the cellular receptors being labeled, and 
become a barrier for the widespread application of QDs in biomedical imaging. Thus, 
how to obtain water-soluble QDs with high quantum yield and high stability remains a 
great challenge. 
No matter what method was used to dissolve the quantum dots in water, for 
biological applications the QDs needs to be purified, such as ultrafiltration, dialysis and 
other methods to remove excess chelators. In addition, the surface of the quantum dot can 
affect the biological and physical characteristics of the quantum dots and the thickness of 
the coated quantum dots will also affect the entire physical dimensions [4].  
The use of quantum dots to observe molecular events in biology has become one 
of their most intriguing applications. For biological applications, further bioconjugation is 
needed since there are not any recognition sites on common polymers.  
 
Figure 2.4. QDs coating and bioconjugation methods (from Smith et al. [4]) 
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2.2.3 Bioconjugation of QDs 
Biological specificity can be rendered by coupling to peptides, proteins, aptamers, 
nucleotides, polysaccharides, or small molecule ligands. Methods used to modify 
aqueous nanocrystals with bioaffinity molecules fall under several broad categories, with 
applicability dictated by the specific nanocrystal surface coating. Nanocrystals with 
accessible surface atoms can directly interact with biomolecules that contain chelating or 
strongly basic residues. This method has been used to successful tag quantum dots coated 
with hydrophilic thiol ligands using peptides and nucleotides with reduced thiols [98, 99] 
and recombinant proteins containing histidine tags [100, 101]. These methods are 
generally not applicable for nanocrystals coated with thick hydrophobic bilayers, which 
have sterically inaccessible surface facets. 
The most commonly used coupling scheme is the covalent coupling between 
functional groups of the organic surface coating and functional groups on proteins or 
other biomolecules. This typically involves amide bond formation between carboxylic 
acid groups on the quantum dot and primary amines on proteins using carbodiimide 
chemistry [32, 94]. This method is more specific, resulting in more predictable 
crosslinking geometries and reduced aggregation, especially for antibody-quantum dot 
coupling. 
Bioconjugation may also be approached through a more modular direction using 
high-affinity streptavidin-biotin binding. Quantum dot-streptavidin conjugates are 
convenient for indirect binding to a broad range of biotinylated biomolecules, which are 
widely available commercially [31]. Biocompatible quantum dots are now commercially 
available, conjugated to a variety of functional biological molecules, like streptavidin, 
biotin, or monoclonal antibodies. Currently, bioconjugation methods are a major limiting 
step in the production of quantum dots for bioimaging applications due to the poor 
efficiency, specificity, reproducibility, scalability, and versatility of most coupling 
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schemes, and due to the inability to control the stoichiometry and geometry of binding 
[102]. 
More complex and specific bioconjugation methods are currently in development, 
including nickel-NTA-histidine interactions, SNAP-tagging, HALO-tagging, and 
crosslinking to glycosylated residues on proteins [32, 103]. 
2.3 Biological applications of Quantum Dots 
Due to their novel optical and electronic properties, semiconductor QDs are being 
intensely studied as a new class of nanoparticle probe for molecular, cellular, and in vivo 
imaging [4, 104-122]. 
2.3.1 Fixed cells and tissue staining 
Cell and tissue staining is an application that has received considerable attention 
for the use of QDs [31, 123, 124]. The fluorescence properties of QDs make them ideally 
suited for this type of application. Of particular interest for these applications are their 
photostability and the ability to excite multiple QDs colors simultaneously. As shown in 
Figure 2.5, Pseudocoloured image depicts five-colour QDs staining of fixed human 
epithelial cells. Cyan corresponds to 655-nm Qdots labelling the nucleus, magenta 605-
Qdots labelling Ki-67 protein, orange 525-Qdots labelling mitochondria, green 565-
Qdots labelling microtubules and red 705-Qdots labelling actin filaments [3]. Many 
different cellular antigens in fixed cells and tissues have been labeled using quantum 
dots, including specific genomic sequences [125], plasma membrane proteins [31], 
cytoplasmic proteins [25] and nuclear proteins, and it is apparent that they can function as 
both primary and secondary antibody stains. In addition, high resolution actin filament 
imaging has been demonstrated using quantum dot [31] , It is now clear that quantum 
dots are superior to organic dyes for fixed cell labeling. 
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Figure 2.5. Pseudocoloured image depicting five-colour QD staining of fixed human 




Figure 2.6. Multiplexed molecular profiling of FFPE tissue sections. (from Maksym 
V. Yezhelyev et al. [5]) 
 
 
Tissue staining is proving to be another exciting application for QDs [32]. The 
potential for multiplexing opens the possibility of a QD revolution for molecular imaging 
in cells and pathological analysis of tissues. As shown in Figure 2.6, up to five 
biomarkers have been simultaneously imaged in clinical tissue samples. Different 
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patterns of nuclear, cytoplasmic and cell membrane fluorescent signals were detected by 
microscopy (left panels, pseudo-color) and expression of these biomarkers was quantified 
by wavelength-resolved spectroscopy (right panels) [5], with the potential for even higher 
degrees of multiplexing. The optical stability of QDs also makes them attractive for this 
application, where samples are often stored and may be revisited at a later time for a 
second opinion or reanalysis. 
2.3.2 live cell imaging 
Quantum dots have found many applications in living cells targeting and 
identifying membrane antigen recognition [126]. In 2002 Thomas Jovin and coworkers 
coupled red-light emitting (CdSe)ZnS nanocrystals to epidermal growth factor, a small 
protein with a specific affinity for the erbB/HER membrane receptor[127]. Maxime 
Dahan and coworkers similarly reported that quantum dots conjugated to an antibody 
fragment specific for glycine receptors on the membranes of living neurons allowed 
tracking of single receptors [128]. These applications have inspired the use quantum dots 
for monitoring other plasma membrane proteins such as integrins [129] and G-protein 
coupled receptors [130] . 
A variety of techniques have been explored to label cells internally with quantum 
dots using passive uptake, receptor-mediated internalization, chemical transfection, and 
mechanical delivery. Quantum dots have been loaded passively into cells by exploiting 
the innate capacity of many cell types to uptake their extracellular space through 
endocytosis [131]. Quantum dots have also been successfully delivered to cells using 
cell-penetrating peptides such as polyarginine and HIV-1 Tat [132, 133]. Nie and 
coworkers used Tat peptide-conjugated quantum dots to examine the cellular uptake and 
intracellular transport of nanoparticles in live cells, and confirmed previous reports of a 
macropinocytosis internalization mechanism [29]. Recently a novel method for three-
dimensional localization for tracking the three-dimensional movements of single protein-
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conjugated Quantum Dots in living cell was presented by out-of-focus imaging with 
diffraction pattern recognition. They localize commercially available Quantum Dots in 
living cells with accuracy better than 7 nm over 2 microns depth [134]. 
2.3.3 In vivo animal imaging 
In vivo molecular imaging using QDs has also been reported [97, 135-150]. 
Tumor imaging is a big challenge, not only because of cancer imaging requires high 
sensitive and specific contrast agents, but of because of the cancerous tissue has inherent 
unique biological properties. During the tumor-induced angiogenesis, the blood vessels 
form abnormally erratic architectures and have wide endothelial pores, which are large 
enough to allow the extravasation for the large macromolecules up to ~400 nm in size, 
thus accumulate in the tumor microenvironment [151]. This ‘enhanced permeability and 
retention’ effect (EPR effect) has inspired the development of many nano-therapeutics for 
the treatment and imaging of cancer. Also the surface receptors on the cancer cells may 
be used as active targets of bioaffinity molecules. In developing imaging probes, active 
targeting cancer antigens got a lot of attention, because it can be used to detect early 
cancers and their metastasis. Semiconductor QDs were very promising in these 
applications due to their strong fluorescent signals and multiplexing capabilities, which 
allow a high degree of sensitivity and selectivity in cancer imaging with multiple antigens 
[4]. 
In 2004 Nie and coworkers demonstrated that tumor targeting with quantum dots 
could generate tumor contrast on the scale of whole-animal imaging [152]. These 
nanocrystals were conjugated to an antibody against the prostate-specific membrane 
antigen (PSMA), and were intravenously injected into mice bearing subcutaneous human 
prostate cancers [6]. Since that work, there have been a number of exciting studies 
showing the utility of QDs as in vivo imaging agents. Using similar methods, Ququan 
Wang and coworkers were able to actively target and image mouse models of human 
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liver cancer using quantum dots conjugated to an antibody against alpha-fetoprotein 
[153], and the group of Xiaoyuan Chen showed that labeling quantum dots with RGD 
peptides significantly increased their uptake in human glioblastoma tumors [154]. 
 
Figure 2.7.  Simultaneous in vivo imaging of multicolor QD-encoded microbeads. 
(From Gao et.al. [6]) 
 
2.3.4 Challenges and opportunities 
Many concerns have been raised over the application of quantum dots in living 
cells and animals due to their chemical composition of toxic heavy metals like Cd. Some 
studies have indicated that the cytotoxicity of QDs strongly correlates with the stability 
and surface coatings of these nanoparticles and many preliminary studies have shown that 
toxicity issues for QDs in vivo are of some concern [6, 31, 37, 38]. Although this could 
eventually prevent their use in vivo, immunohistological and cellular and tissue staining 
is performed on in vitro or ex vivo clinical samples, where heavy metal toxicity is 
consequential. As a result, the use of multicolor QD probes for tissue staining and 
biomarker detection is likely one of the most important and clinically relevant 
applications in the near term [32, 155]. 
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The applications of quantum dots in biomedicine span a broad range of length 
scales and address a lot of clinical and biological sensing needs. Despite the many assets 
of these probes, many challenges must be overcome. The colloidal and surface properties 
of these nanoparticles must be optimized in order to maximize their stability, minimize 
nonspecific binding, and minimize their size. For biomedical applications, ideal QDs 
should not only have good water solubility, high stability, minimized cell toxicity, but 
also have abundant functional groups such as amine (–NH2) and carboxyl (–COOH) 
groups for further conjugation toward specific targeted imaging.  
In the future, the major goal for bio-nanotechnology is to develop complex 
biological probes and agents that can be used to monitor and specifically manipulate 
biological systems, most importantly for medical applications. The nanocrystal probes 
designed from quantum dot backbones have already reached an impressive level of 
layered complexity, and probes with multimodal imaging and drug delivery capabilities 
are in development [12, 17, 143, 156-188]. They have been the topic of many efforts to 
develop probes that are detectable by both optical imaging and other modalities such as 
PET or MRI [21], such as lipid-coated multimodality QDs[58, 59], doped QDs with Mn 
into the core matrix of the QDs [22, 60], and QDs conjugates with DOTA and DTPA to 
the surface to metalate PET or MRI active molecules [55-57, 189]. Increasing the 
precision, dimensionality, and multimodality of these particles may generate great 
advances throughout biomedical fields, such as for cancer detection, profiling and 
treatment and even for other diseases. 
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Figure 2.8. Applications of quantum dots as multimodal contrast agents in 




BIOCOMPATIBLE HYALURONIC ACID-CYSTAMINE POLYMER 
COATED QDS FOR CANCER CELL IMAGING 
 
   
Abstract 
 The cysteamine-modified hyaluronic acid (HA) polymer was employed to coat 
quantum dots (QDs) through a convenient one-step reverse micelle method, with the final 
QDs hydrodynamic size of around 22.6 nm. The HA coating renders the QDs with very 
good stability in PBS for more than 140 days and resistant to large pH range of 2–12. 
Besides, the HA- coated QDs also show excellent fluorescence stability in BSA-
containing cell culture medium. In addition, the cell culture assay indicates no significant 
cytotoxicity for MD-MB-231 breast cancer cells, and its targeting ability to cancer 
receptor CD44 has been demonstrated on two breast cancer cell lines. The targeting 
mechanism was further proved by the HA competition experiment. This work has 
established a new approach to help solve the stability and toxicity problems of QDs, and 
moreover render the QDs cancer targeting property. The current results indicate that the 
HA polymer-coated QDs hold the potential application for both in vitro and in vivo 
cancer imaging researches. 
3.1 HA applications and the mechanism for targeting CD44 receptor 
3.1.1 Hyaluronic Acid 
Hyaluronic acid (HA) is a glycosaminoglycan, which presents in the extracellular 
matrix of many parts of the body cell. As an important biological material, HA has a very 
wide range of applications in different fields, such as tissue culture scaffolds and 
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cosmetic materials [190]. Here we describe the structure and properties of HA and give 
several examples on the applications of HA in tissue engineering and nanocarriers for 
controlled delivery.  
HA structure and properties 
Hyaluronic acid is an anionic, non-sulfated, linear polysaccharide which consists 
of disaccharide units of d-glucuronic acid and N-acetyl-d-glucosamine linked together by 
β-1,4 and β-1,3 glycosidic bonds, as shown in Figure 3.1 [8].  
 
Figure 3.1. The structure of HA 
 
HA can be extracted from animal products or produced by bacterial fermentation 
(such as Bacillus subtilis) to obtain controllable molecular weight. It exists in the 
synovial fluid and natural extracellular matrix and is an important component of 
connective tissue, epithelial tissue, and nerve tissue. In addition, HA is biocompatible and 
hydrophilic and can form a lower concentration of viscous solution, which promotes 
wound healing by promoting cell migration and proliferation. Moreover, HA can be 
degraded by hyaluronidase and reactive oxygen species in mammals, producing low 
molecular weight HA and oligosaccharides. HA can interact with several cell surface 
receptors such as CD44, CD54 and CD168 which makes it very popular in a lot of 
controlled delivery applications [8]. 
Application of HA in tissue engineering 
The scaffold is a temporary supporting structure for growing cells and tissues by 
definition and also called synthetic extracellular matrix, which plays an important role in 
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supporting cells [191]. HA offers many advantages as a tissue scaffold. First, it is 
biodegradable, biocompatible and is a major component of connective tissues that play an 
important role in cell differentiation and growth. Second, HA has a lot of functional 
groups such as carboxylic acids and hydroxyl groups which can introduce functional 
domains to form hydrogel by crosslinking. Thirdly, HA has low non-specific adsorption 
of proteins, and they can have specific interactions between the scaffold and growing 
cells through cell receptors such as CD44 and RHAMM to facilitate tissue growth and 
repair [190]. 
The development of 3D cellular scaffold in tissue engineering has been 
intensively studied in recent years. Because HA has a lot of functional groups such as 
carboxylic acid, hydroxyl groups and N-acetyl group, it offers a lot of strategies for HA 
photopolymerization. The photocrosslinkable HA hydrogels can be formed through the 
covalent carboxylic acid or hydroxyl groups by reacting the polymer with functional 
groups, such as methacrylates under homogeneous (such as water) or heterogeneous (e.g., 
water/DMSO) conditions [8]. As shown in Figure 3.2A, a versatile bioink for 3D printing 
of high-resolution scaffolds was developed. The scaffolds were based on thermal- and 
photo-triggered tandem gelation through the blending of thermos-responsive polymer 
poly (N-isopropylacrylamide) grafted hyaluronan (HA-pNIPAAM) and methacrylated 
hyaluronan (HAMA) and scaffolds of good viability can be printed by this novel method. 
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Fig. 1. (a) The variation in G0/G00 is schematically illustrated for the different stages of bioprinting with a thermoresponsive polymer. (b) The gelation mechanism in which
HA-pNIPAAM forms a physical gel (only the isopropyl groups of pNIPAAM are depicted).
Fig. 2. Schematic illustration of the fabrication of 3-D constructs for cartilage engineering: (a) thermal crosslinking of the bioink maintains the printed shape; (b)
establishment of a mechanically stable secondary network with UV crosslinking; (c) elution of the transient matrix; (d) implantation into a cartilage lesion.
164 M. Kesti et al. / Acta Biomaterialia 11 (2015) 162–172
 
Figure 3.2. Schematic illustration of HA-based 3-D constructs for cartilage engineering. 
(from Pereira et al. [8]) 
 
HA-based nanocarriers for controlled delivery 
Among the several drug delivery materials that was using now, polysaccharides 
are a kind of attractive molecules because they can undergo a large range of chemical 
modifications and they are biocompatible, biodegradable, and have relatively low 
immunogenicity. Therefore, polysaccharides have been widely used in delivery of many 
types of drugs [9]. There’re a lot of advantages for the conjugation of chemotherapy 
drugs to macromolecules, as shown in Figure 3.3. Macromolecules help to improve the 
drugs’ pharmacodynamics (PD) and pharmacokinetics (PK) by different mechanism. For 
the PD aspect, macromolecules have a high drug loading ability and also can conjugate 
targeting molecules to improve the specificity of the drugs. As for the PK aspect, 
macromolecules can increase the blood circulation time and reduce the volume of 
distribution.  Also, the bigger size of the polymer–drug conjugates can get to the tumor 
sites due to the enhanced permeability and retention (EPR) effect. 
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Figure 5. Advantages of chemotherapy agent conjugation with macromolecules. 
Macromolecules can ameliorate drugs’ pharmacokinetics (PK) and pharmacodynamics (PD) by 
different phenomena. Regarding PD, macromolecules have high drug loading capacity and, in addition, 
can be equipped with targeting molecules to increase drug specificity. In some cases, stimuli-responsive 
delivery has been studied to improve drug release in cancer tissues. In this regard, for example,  
pH-sensitive drug delivery systems take advantage of the different pH in normal (pH~7.4) vs. cancer 
(pH < 6) tissue [72]. With regard to PK, macromolecules can increase blood circulation time, reduce the 
volume of distribution and prolong the distribution/elimination phases [73]. It is also noteworthy that,  
in general, polymer–drug conjugates are not able to cross the endothelium surrounding healthy vessels. 
This mostly depends on the bigger size of polymer–drug conjugates compared to endothelium 
fenestration. In contrast, in pathological conditions like cancer, local vessels are more permeable due to 
the increased size of endothelium fenestration. Through these gaps, the delivery systems can extravasate 
and reach the tumor where they tend to reside due to the scarce lymphatic drainage. Collectively these 
phenomena go under the name of enhanced permeability and retention (EPR) effect [74]. The use of 
materials able to release the drug slowly, may further improve drug residence at the tumor site, possibly 
ameliorating drug efficacy and reducing side effects. 
The use of macromolecule-based delivery systems also allows facing more complex clinical 
problems. For instance, it is possible to design multidrug delivery systems to improve, on one hand,  
the treatment efficacy and, on the other hand, the compliance of the patients. Another interesting option 
is related to the possibility to design so called “theragnostic” agents, that render possible the 
simultaneous cancer diagnosis and therapy. This approach typically combines the use of a therapeutic 
agent together with a targeting/marker agent, as below detailed. 
Based on the above considerations, chemotherapeutic drugs have been encapsulated, conjugated or 
linked to different carriers [75]. Among these, biopolymers have been frequently used due to their 
biocompatibility, natural occurrence, often targeting ability, relatively inexpensiveness and the possibility 
of derivatization with different chemical groups [76].  
  
 
Figure 3.3 Advantages of drug delivery systems of chemotherapy agent conjugated with 
macromolecules (from Posocco et al. [9]) 
 
Hyaluronic Acid conjugates have been used as nanovectors for drugs, genes and 
nanocompo ite for the active targetin  in canc r diagnosis and tr atmen  [192]. 
Hyaluronic acid receptor CD44 is found to overexpress in many cancer cells, particularly 
in tumor-initiating cells, whereas lower level of CD44 receptors are found on the surface 
of other non-tumor cells, such as epi helial, hematopoietic, and neuronal cells. Therefore, 
HA has attracted a lot of interest in the development of novel drug delivery systems in 
different types of nanovectors, serving as targeting ligand in preparation of actively 
targeted nano-platforms for a lot of genes, drugs, and diagnostic agents [192].  
HA has been widely used in RNAi delivery due to its great advantages mentioned 
above. Development of nontoxic, tumor-targeting, and in vivo RNAi delivery system was 
usually a hard work. In a study as shown in Figure 3.4, the researchers developed a 
versatile RNAi nanoplatform which is based on a tumor-targeting and pH responsive 
RNA nanocarrier [10]. This nanoplatform for RNA delivery contai s four compon nts 
which are a hydrophilic HA shell as CD44-targeting ligand, hydrophobic 5β-cholanic 
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acid (CA) core as drug reservoir, phosphate receptor Zn(II)-dipicolylamine (DPA/Zn) as 
RNA binding site and a calcium phosphate layer. The nanocarrier can distribute the 
RNAs into the cytoplasm of the cancer cells uniformly and selectively suppress the target 
gene expression. This nanoplatform can serve as a versatile delivery system for RNAi 
applications, and this work may open up new possibilities for RNA-based cancer 




Figure 8. HA-based delivery for siRNAs proposed by Choi et al. [38]. 
3.2.5. Dextran Based Delivery 
Thus far, several types of dextran-based NPs have been generated for NABD delivery. From the first 
attempt where dextran alone was bound via electrostatic interaction to NABDs, more complex solutions 
have been proposed. For example, Naeye et al. decorated the dextran/NABDs NPs with a hydrophilic 
PEG shell for the intravenous delivery route [130,131]. Whereas PEGylation did not prevent the partial 
dissociation of NABDs in human plasma, it was able to prevent NPs aggregation and the lysis of red 
blood cell. However, a clear charge dependent interaction with platelets and leukocytes was observed. 
On one hand, these results suggest the positive NPs features able to prevent a significant interaction with 
red blood cells; on the other hand, they indicate that further improvements aimed at the reduction of 
platelet interaction are necessary. 
Another example of dextran NPs modification consisted in the conjugation of an acetal-modified 
dextran (Ac-DEX) with spermine as NABD delivery material [47]. The cationic nature of spermine 
improved the NPs complexation with the negatively charged siRNA and facilitated the cell membrane 
binding. Additionally, the Ac-DEX-spermine NPs resulted to be efficiently released from endosome, 
thus allowing the siRNA distribution with the cell cytoplasm [48]. This in turn resulted in an efficient 
silencing of the expression of the luciferase gene in HeLa cells expressing luciferase. 
Very recently, dextran was used to encapsulate NPs containing NABD and PEI [49]. In particular, the 
authors encapsulated NABD/PEI with multiple layers of dextran sulfate (DexS) and poly-L-arginine 
(pArg). The idea below this approach is that the DexS/pArg layers can protect the NABD in the 
 
Figure 3.4. HA-based RNAi elivery nano-platform for siRNAs (from Choi et al. [10]) 
 
3.1.2 CD44 receptor 
CD44 is a single chain glycoprotein and a multi- tructur l a d multi-functional 
cell surface molecule. CD44 involves in a lot of cell activities, such cell proliferation and 
diff rentia ion, c ll migration, angiogenesis, presentation f cytokines, chemokin s, and 
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growth factors to the corresponding receptors, and the docking of proteases at cell 
membrane, and in the signaling for cell survival. The discovery that CD44 receptor is 
crucial on many tumor cell activity has given new hope in the scientific and medical 
research. Its multi-structural and pleotropic nature was revealed by the biochemical 
characterization, allows the targeting of malignant cells, which express CD44 receptors. 
The principal ligand of the CD44 receptor is hyaluronic acid and CD44 can be activated 
by fragmented HA (molecular mass <5 × 105D), but not the high molecular mass HA 
(>106D) [193]. 
CD44 can mediate the internalization and metabolism of HA, and various cell 
types in normal tissues have low levels of endogenous expression, but it needs to be 
activated before they can bind HA [194]. CD44 can transit from the inactive, low-affinity 
state to an active, high-affinity state after cell activation such as antigen receptors 
ligation, sulfation, or the action of cytokines and will be capable of binding HA. Unlike 
normal cells, tumor-derived cells express the high-affinity state of CD44, thus is capable 
of binding and internalizing HA. Furthermore, CD44 is reported to interact with HA of 
minimum length of 6–8 saccharide units [195]. Therefore, there are several possible 
strategies for cancer treatment, such as interference with the HA-CD44 interaction, 
targeting drugs to CD44 or HA matrix. 
CD44 involves in many pathways such as activation of cell cycling and 
proliferation, cytoskeleton reorganization, cell migration and maintenance of cell 
survival, which are highly related with the malignant process, therefore, CD44 is 
associated with aggressive type of tumors in many cases. There is an upregulation of 
CD44 in many cancers of epithelial origin [65]. Overexpression of CD44 isoforms in 
malignant tissues has been already detected in some of the patients compared with the 
control counterparts, in several diseases including breast and colorectal malignant tissue, 
lung cancer (squamous cell carcinoma; adenocarcinoma; large cell carcinoma; small cell 
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carcinoma), hepatocellular carcinoma, renal cell carcinoma, gallbladder carcinoma, 
ovarian (mostly clear cell) carcinoma, endometrial cancer and melanoma [193]. 
In conclusion, CD44 can be a promising targeting molecule for the therapy and 
diagnosis of several human cancers [193]. HA has already been used as drug carrier and 
ligand on liposomes or nanoparticles to target the drugs to CD44 overexpressing cells. 
The drugs can be attached to HA through the carboxyl group on the glucuronic acid 
residue or the hydroxyl group on the N-acetylglucosamine [65]. HA targeting will 
increase drug accumulation in the CD44 overexpressing cells and HA conjugated drugs 
can enter the cells via endocytosis. 
3.1.3 HA-based CD44 targeted imaging using QDs 
A number of work has been done using QDs for HA-CD44 targeted imaging. 
Hahn’s group has reported a series of work using adipic acid dihydrazide-modified HA to 
conjugate commercial carboxyl Quantum Dots for in vivo imaging, and found that lower 
carboxyl-modified HA (i.e., 35, 22 %) kept the targeted ability for HA receptors in liver, 
while higher modification ratio (i.e. 50, 68 %) of HA will lose much of HA targeting 
ability [11, 196-198].  
 
Figure 3.5. Synthesis of a hyaluronic acid−quantum dot (HA-QDot) conjugate using 
adipic acid dihydrazide-modified HA (HA-ADH) (from Kim et.al. [11]) 
 
Graphene quantum dot (GQD) has also been conjugated with hyaluronic acid 
(HA) (GQD-HA) as a targeting agent and in vitro cellular imaging exhibited strong 
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fluorescence from CD44 overexpressed A549 cells. In vivo investigation on CD44 
receptor overexpressed tumor-bearing balb/c female mice also demonstrated more bright 
fluorescence from the tumor tissue [199]. 
Fluorescent nanosized carbon dots (Cdots) were also reported for the application 
of real time bioimaging of target specific delivery of hyaluronic acid (HA) 
derivatives. Polyethylene glycol (PEG) diamine-capped Cdots were synthesized for HA-
Cdot conjugates by amide bond formation between amine groups of Cdot and carboxylic 
groups of HA.  In vitro bioimaging was realized for target specific intracellular delivery 
of the HA-Cdot conjugates through HA receptor-mediated endocytosis. Furthermore, in 
vivo real-time bioimaging of Cdots and HA-Cdot conjugates proved the target specific 
delivery of HA-Cdot conjugates to the liver with abundant HA receptors [200]. Those 
work in previous studies are good examples for the application of QDs in HA-CD44 
targeted imaging. 
3.2 Materials and Methods 
3.2.1 Materials 
Chemicals and instruments 
Sodium hyaluronate with MW of 7500 was purchased from Lifecore (USA). 
Cystamine dihydrochloride, dithiothreitol (DTT), cyclohexane, IGEPAL CO-520, 
tetramethylammonium hydroxide (TMAH), ethylene- diaminetetraacetic acid (EDTA), 
and Ellman’s reagent were purchased from Sigma-Aldrich. EDC, sulfo-NHS, and 
cysteine hydrochloride monohydrate were purchased from Pierce. UV–Vis absorption 
spectra were obtained using a Cary 100 Bio UV–Visible Spectrophotometer from Varian 
Company. Photoluminescence spectra were recorded by a Fluoromax 2 
spectrofluorometer. Dynamic light scattering measurements were performed on a 
Brookhaven 90Plus Particle size analyzer. Transmission electron microscopy was 
performed on a Hitachi H-7500 TEM at the Electron Microscopy Core Facility at Emory 
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University. 96-well plates were read by a Synergy 2 Multi- Mode Microplate Reader 
(Biotek, USA). 
3.2.2 Methods 
Synthesis of HA-cysteamine polymer 
The synthesis of HA-cysteamine polymer involves two steps: synthesis of HA-
cystamine polymer and reduction of the disulfide bond of cystamine by DTT. Typically, 
sodium hyaluronate with average MW of 7500 was dissolved in PBS, then 18 molar 
excess of EDC and 18 molar excess of sulfo-NHS were added to the HA sodium salt 
solution, and the mixture was stirred for 1 h to activate the carboxyl groups. Then 12 
molar excess of cystamine dihydrochloride in PBS was added dropwise while stirring, 
and the mixture was kept reacting overnight. The HA-cystamine product was purified by 
dialyzing against 1X PBS buffer using MWCO 3500 dialysis tube. For DTT reduction of 
the disulfide bond on cystamine, 5 molar excess of DTT was added to HA-cystamine 
solution and stirred for 24 h. The final product was purified by dialyzing against pH 3 
buffer using MWCO 3500 dialysis tube. The water was removed by lyophilizing for 2–3 
days. Finally cotton-like HA-cysteamine polymers were obtained. The final product 
should be stored at -20 °C to protect the active thiol groups from being oxidized. 
Determination of reactive thiols on HA- cysteamine polymer 
The sulfhydryl group concentration on HA-cysteamine polymer was determined 
via Ellman’s reagent by comparing to a standard curve composed of known 
concentrations of cysteine. Namely, 0.1 M sodium phosphate buffer of pH 8 containing 1 
mM EDTA was prepared as reaction buffer. 4 mg Ellman’s Reagent was dissolved in 1 
ml of reaction buffer as Ellman’s reagent solution. A set of cysteine standards were 
prepared by dissolving cysteine hydrochloride mono- hydrate at concentrations of 0, 0.25, 
0.5, 0.75, 1, 1.25, and 1.5 mM in reaction buffer. 250 µl of each cysteine standard or HA-
cysteamine polymer of known weight was added to separate test tubes, which contain 50 
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µl of Ellman’s reagent solution and 2.5 ml of reaction buffer. The mixture was incubated 
at room temperature for 15 min. Then the absorbance at 412 nm was measured using a 
plate reader and the standard curve was plotted. Finally, the active thiol group 
concentration of the HA-cysteamine polymer was determined accordingly. 
Synthesis of (CdSe)CdZnS QDs and encapsulation with HA-cysteamine polymer 
(CdSe)CdZnS QDs of 645nm emission wavelength were synthesized following 
previous methods [87, 201]. When encapsulating QDs with HA-cysteamine polymer, a 
modified reverse micelle method was used [94, 202]. Typically, 0.64 nmol QDs in 
hexane was dried by vacuum to get a thin film, then 9 ml cyclohexane was added until 
the QDs was fully dissolved. Next 1 ml IGEPAL CO-520, 10 mg HA-cysteamine 
polymer in 500 µl water and 3.61 mg TMAH in 200 µl methanol were added to form 
reverse micelle. The solution should be clear after adding all these reagents. If not clear, 
add more IGEPAL CO-520 or water. The mixture was sonicated for 5 min, and votexed 
for 60 min. Then 1-2 ml ethanol was added to precipitate the HA-cysteamine polymer 
coated QDs. The pellets was washed with additional ethanol for 3 times and re-dispersed 
in 1X PBS. After centrifuging the QDs solution at 5000 g for 10 minutes to get rid of the 
undissolved parts, the supernatant which contains the HA-cysteamine coated QDs was 
purified using a 0.2 µm syringe filter. 
pH stability test 
An "universal" pH buffer, Britton–Robinson buffer with pH range from 2 to 12 
were prepared [203]. Then a same amount of concentrated QDs were added to each pH 
solution. The QDs solution were added in fluorescence testing tubes and sealed well with 
parafilm. After 1 h, 16 h and 24 h incubation at room temperature, the photoluminescence 
of QDs were recorded by a fluorometer and integrated intensity was calculated for 
comparison. The fluorescence intensity of QDs in pH 7 buffer after 1h incubation was 
referenced as 1, and others were scaled as certain percent ratio. The corresponding 
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fluorescence images of QDs after 24 h incubation were taken by illuminating with a 365 
nm hand-held UV lamp. 
Long-time stability test 
Long-time stability of the HA-polymer coated QDs was tracked for 5 months and 
compared with mercaptoacetic acid (MAA) coated QDs. Typically, 300 µL HA-polymer 
coated QDs in 1X PBS buffer at a concentration of 25 nM was added in a fluorescence 
testing tube and sealed well with parafilm. The QDs containing tube was stored in 4°C 
refrigerator and the fluorescence intensity was tested on certain days. To prepare MAA-
coated QDs, 150 µl QDs of 10 nM in crude stock were precipitated with 13 ml acetone. 
The pellets were washed with acetone and re-dispersed in 1ml chloroform. 500 µl MAA 
and 100 mg TMAH in 500 µl methanol were added. The whole solution was sonicated 
for 10 min and kept at 60°C water bath for 1 h. The QDs were precipitated with acetone 
by centrifuge at 8000 g for 10 min, washed with acetone and dissolved in 1X Borate 
buffer. The QDs were dialyzed against 50 mM borate buffer (pH 8.5) using 20K MWCO 
dialysis tube, and then stored at 4ºC in the dark. The fluorescence intensity was integrated 
for each spectrum and compared with the first day’s result. 
Cell culture medium stability test 
The stability of HA-QDs in cell culture medium was tested and compared with 
the commercial carboxyl 655 nm QDs from Invitrogen. Typically, the HA-QDs and 655 
nm carboxyl QDs from Invitrogen were diluted in PBS or DMEM phenol-red free 
medium with 10% fetal bovine serum (FBS) added. The QDs were sealed and put under 
room temperature without any protection from light. At 0 h, 1 h, 16 h and 24 h, the 
fluorescence of these QDs were tested and integrated. The integrated fluorescence 
intensity of each QDs in PBS at 0 h were set as 1 and all results were referenced to get 
certain percent ratio.  
Cytotoxicity test 
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MD-MB-231 breast cancer cell line was cultured in RPMI 1640 with 10% FBS 
and 1% streptomycin and penicillin antibiotics. On the first day, cells were seeded on a 
96 well plate at 5×103 cells/well. After 24 h culture, QDs were added to the 4, 10 and 25 
h incubation time group with the final concentrations of 1, 5, 10 and 20 nM.  For the 
control group, cells of same number were seeded but no QDs were added.  This is 
regarded as 100% cell viability. A blank control with no cells and QDs but only cell 
culture medium was used as 0% cell viability. Experiments were triplicated. After 
incubation with QDs, the medium was aspirated and 100 µl of new cell culture medium 
and 10 µl Cell Counting Kit-8 solution was added to each well. Following incubation 
with cells at 37°C for 3 h, the absorbance at 450 nm was measured by a plate reader. 
Cancer cell targeted imaging 
CD44+ MD-MB-231 and MCF-7 breast cancer cells were used for targeted 
imaging and NIH/3T3 fibroblast cell was used as a negative control. Due to the different 
growth speed, NIH/3T3 fibroblast cells were seeded at 3500 cell/well and MD-MB-231 
and MCF-7 breast cancer cells were seeded at 25×103 cell/well on 8-well chamber slides. 
After 24 h growth, cells were washed with 1X PBS buffer and then fixed with 200 µl 4% 
formaldehyde and 0.25% Triton X-100 in PBS for each well. After 15 min, cells were 
washed with PBS for 5 min, three times. 200 µl blocking buffer of 6% bovine serum 
albumin (BSA) in PBS were added to each well and incubated for 1 h. Then blocking 
buffer was aspirated and 200 µl HA-cysteamine polymer coated QDs were added to each 
well, with final concentrations of 1, 5, 10 and 20 nM in blocking buffer. After 1 h 
incubation, each well was washed with PBS three times for 5 min each. The slides were 
mounted with anti-fade mounting media containing DAPI. The slides were imaged under 
Olympus IX71, using 20X objective. 
Hyaluronic acid competitive inhibition test 
MCF-7 cells were seeded on an 8-well chamber slide at 30 k/well for overnight 
growth. The fixation, permeabilization and blocking procedure are the same with the 
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targeted imaging experiment. Before adding QDs, different concentrations of 200 µl HA 
in blocking buffer were added to each well for 1 h. HA concentrations used are 0 nM (as 
control), 10 nM, 100 nM, 1 µM, 10 µM, 100 µM, 1 mM and10 mM. Then HA solution 
was aspirated and 200 µl QDs at final concentration of 10 nM in blocking buffer were 
added to each well. After 1 h incubation, the QDs was washed with PBS and mounted, 
and the slide was imaged under Olympus IX71, using a 20X objective. 
3.3 Results and Discussions 
3.3.1 Results 
Synthesis and characterization of HA-cysteamine polymer 
As shown in Figure 3.6(a), the amine group of cystamine was first covalently 
conjugated to the carboxyl group on HA using EDC and sulfo-NHS. Then the disulfide 
bond of cystamine was further reduced with DTT to get the final HA-cysteamine 
polymer. Each polymer molecule contains approximately 8 active thiols, as determined 
via Ellman’s method. Averagely, an HA molecule with MW 7500 contains about 19 
carboxyl groups, therefore about 42% carboxyl groups on HA have been converted to 
thiol groups. This thiol modification ratio can ensure strong binding of the HA polymer 
on QDs surface and also, a large amount of carboxyl groups are left to maintain the HA 
targeting ability for CD44 receptor on cell surface.  
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Figure 3.6. Preparation of HA-cysteamine polymer-coated QDs. (a) The chemical 
synthesis of HA-cysteamine polymer. (b) Schematic illustration of HA polymer coating 
on QDs 
 
Preparation and characterization of HA-cysteamine polymer coated QDs 
Polymer coated QDs were synthesized using an adapted reverse micelle method 
for ligand exchange and phase transfer reaction [94, 202] as shown in Figure 3.6(b). 
Hydrophobic QDs protected with oleylamine on surface was synthesized by traditional 
methods. [87, 201]   For ligand exchange, the hydrophobic QDs were first dispersed in 
cyclohexane. With the addition of IGEPAL CO-520 and HA-cysteamine polymer 
dissolved in water, a reverse micelle was formed. TMAH was used as a phase transfer 
catalyst to induce the reaction. After the reaction, water soluble QDs coated with HA-
cysteamine polymer were incorporated inside the reverse micelle.  
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Figure 3.7. Schematic illustration of reverse micelle phase transfer procedure for HA-
cysteamine polymer coated QD synthesis.  
 
Figure 3.8(a-b) show representative transmission electron microscopy (TEM) 
images of QDs before and after polymer coating. Both of them appear uniform in size 
and were well dispersed. Figure 3.8(a) shows the crystal size of QDs before polymer 
coating is 9.5 ± 1.3 nm. Negative staining TEM with 1% methylamine tungstate clearly 
shows polymer coated QDs with a thin layer as shown in the inserted plot of Figure 
3.8(b) and the overall size of HA coated QDs is 14.5 ± 1.6 nm. Figure 3.8 (c-d) show UV 
absorption and fluorescence spectra before (Figure 3.8(c)) and after (Figure 3.8 (d)) the 
HA polymer coating. We can see that there is no significant difference between the 2 sets 
of spectra. Quantum yield (QY) calculation was 24% after coating while the QY of QDs 
in hexane before coating is 28.1%. The QY didn’t lose much after polymer coating, 
which proves a good surface protection and passivation.  The dynamic light scattering 
(DLS) results (Figure 3.8 (e)) show that the hydrodynamic size of the compact polymer 
coated QDs is around 22.6±5.2 nm. 
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Figure 3.8. Characterization of QDs. (a) TEM image of QDs in hexane (before polymer 
coating). (b) TEM images of HA-cysteamine polymer coated QDs in water. Negative 
staining TEM is inserted with the same scale bar, showing the polymer coating layer. (c) 
Absorption and fluorescence spectra of QDs in hexane (before polymer coating). (d) 
Absorption and fluorescence spectra of QDs after HA-cysteamine polymer coating, 
showing no significant difference with the spectra before polymer coating. (e) DLS size 
distribution showing a peak hydrodynamic diameter of ~22.6 nm 
 
To exclude the possibility that the hydrophobic part of IGEPAL CO-520 
intercalate into oleylamine on QD surface, and the hydroxyl groups render QDs water 
soluble, control experiment without adding HA-cysteamine polymer was conducted. The 
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final QDs pellets cannot dissolve in water, which proved that it is HA polymer rather than 
IGEPAL CO-520 that makes QDs water-soluble. 
pH stability test 
The colloidal stability of HA-cysteamine polymer coated QDs in different pH buffer from 
2 to 12 was tested. As shown in Figure 3.9 (a), the polymer coated QDs keep great 
fluorescence performance even after as long as 24 h incubation with the extreme pH 
condition. The QDs have better fluorescence performance in basic buffer than in acidic 
buffer. As the incubation time increases at each pH, integrated fluorescence in acidic 
buffer gradually decreases while in basic buffer it increases. This is reasonable 
considering the HA has unmodified carboxyl groups, which makes them more soluble in 
basic solution. However, we can see from Figure 3.9 (b), that after 24 h incubation the 
QDs didn’t precipitate or aggregate and still keeps great colloidal and photo stability even 
for as long as 24 h incubation with pH range from 2-12. This indicates that the QDs can 
adapt to the complex body environment of different pH changes, and they can be good 
candidates as intracellular and in vivo imaging probes for lone time tracking.  
Long-time stability test 
Long-time stability of the HA-polymer coated QDs was tracked for 5 months. For 
the same vial of 25 nM QDs in 1X PBS buffer stored at 4°C, the integrated fluorescence 
intensity didn’t drop much even after as long as 140 days, while a control group using 
MAA coated QDs stored at the same condition precipitated within 11 days, as shown in 
Figure 3.10. The HA-polymer coated QDs shows great long time stability comparing 
with the single thiol MAA coated QDs. This is a good example showing the necessity of 




Figure 3.9. pH stability of HA-cysteamine polymer coated QDs. (a) Normalized 
integrated fluorescence intensity after incubating for 1 h, 16 h and 24 h in different pH 
buffer. The fluorescence intensity of QDs in pH 7 buffer after 1 h incubation was 
referenced as 1.  (b) Corresponding fluorescence images of QDs after 24 h incubation 
(illuminated with a 365 nm hand-held UV lamp) 
 
 
Figure 3.10. Long-time stability of HA-cysteamine polymer coated QDs, compared with 




Stability in cell culture medium 
The QDs stability in FBS containing cell culture medium is very important for 
further cellular and even in vivo imaging applications. If the fluorescence of QDs is easily 
influenced by the cell culture medium, then stable and quantitative continues imaging is 
challengeable. The results of the HA polymer coated QDs were shown in Figure 3.11 (a). 
We can see that those QDs keeps excellent fluorescence stability in cell culture medium 
at room temperature without any protection from the light, and the stability of our HA 
polymer coated QDs are comparable to the commercial carboxyl QDs from Invitrogen 
(Figure 3.11 (b)). The results proved the great cell culture medium stability of the QDs 
and showed the possibility for further cellular applications. 
 
 
Figure 3.11. Stability in cell culture medium of HA polymer coated QDs and commercial 





MD-MB-231 breast cancer cell line was used for cell toxicity test. T-test was 
performed for each group comparing to the control group. As shown in Figure 3.12, no 
significant cytotoxicity was observed in different time and concentration groups, which 
proved great biocompatibility for the HA polymer coated QDs, and show the potential for 
in vivo application in the future. 
 
Figure 3.12. Cytotoxicity test of HA-cysteamine polymer-coated QDs. Dose-dependent 
viability evaluation of MD-MB-231 breast cancer cells treated for 4, 10, and 25 h. The 
experiments were performed in triplicate. 
 
CD44+ Cancer cell targeted imaging 
CD44+ MCF-7 and MD-MB-231 cell lines were used for targeted imaging and 
NIH/3T3 cell line was used as a negative control. QDs with different final concentrations 
of 5 nM and 10 nM have been tested, and shown in Figure 3.13. Obviously, strong 
fluorescence on MD-MB-231 and MCF-7 cell lines was observed but no fluorescence on 
NIH/3T3 cell line can be seen. This result not only demonstrates the targeted ability of 
the polymer coated QDs, but also indicates very little non-specific cellular binding for 
NIH/3T3 cell. Therefore, for future studies, final concentration of 5 nM QDs will be high 
enough for HA targeted imaging. 
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Figure 3.13. Illustration of the targeted imaging of breast cancer cells with HA-
cysteamine polymer-coated QDs with final concentration of 5 and 10 nM. (a) NIH/3T3 
fibroblast cell line shows no QD fluorescence and little non-specific cellular binding. (b) 
MD-MB-231 breast cancer cell line shows strong QD fluorescence of targeted staining. 
(c) MCF-7 breast cancer cell line also shows strong QD fluorescence of targeted staining. 
20X objective was used on an Olympus IX 71 microscope 
 
Hyaluronic acid receptor competitive imaging 
In order to confirm that the staining of breast cancer cell line is receptor mediated, 
we conducted a HA competitive imaging experiment on MCF-7 cell by treating the cells 
with different concentrations of HA before adding of HA polymer coated QDs. As 
presented in Figure 3.14, when HA concentration increases, the QDs fluorescence 
intensity shows a downward trend and QD fluorescence couldn’t be detected at 10 µM 
HA treating dosage. This result is a solid evidence to prove that the mechanism of HA-
QDs to stain the cells is mediated by the HA receptor.  
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Figure 3.14. HA receptor competitive targeted imaging of MCF-7 cell line with HA-
cysteamine polymer-coated QDs treated with different concentrations of HA. (a) Control 
group (no HA), (b) 10 nM, (c) 100 nM, (d) 1 µM, (e) 10 µM, (f) 100 µM, (g) 1 mM, (h) 
10 mM. QD final concentration was 10 nM for all. 20X objective was used on Olympus 
IX 71 microscope. From 1 to 10 µM HA, QD fluorescence intensity has a dramatic 
change, which indicates that the staining is mediated by HA receptor 
 
3.3.2 Discussions 
The current established one-step QDs modification method is advantageous in the 
following three aspects. Firstly, for biomedical applications a targeting moiety like 
antibody, peptide or small molecule should be added to the surface modified QDs, so that 
QDs can be used to target tumor biomarkers as well as tumor vasculatures with high 
affinity and specificity [4]. Because most of the surface coating itself doesn’t have 
targeting ability, thus a following bioconjugation step is necessary. However, it is always 
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time consuming and usually increases the overall size of QDs. Comparing with previous 
multidentate polymer coating methods [44-54], the current method is much simplified. 
By employing the HA polymer as the coating molecules, we have circumvented the 
targeting moiety conjugation step, and produced QDs with not only small size, but also 
CD44 receptor recognition groups, namely the carboxyl groups on HA. 
Secondly, the traditional QDs coating methods, such as single thiol [27, 43] and 
di-thiol coating[204] could not protect the QDs surface very well thus the resulting 
stability is not good enough. And their applications for in vivo imaging are hampered by 
their sensitivity to biochemical environments. In order to get more stable QDs, recent 
efforts have been directed toward synthesizing ligands or polymers with multiple 
functional groups with different backbones and pendant groups. For instance poly 
(methacrylate), [46, 48, 52, 53] poly (acryl acid) (PAA) [44, 47, 49] and poly (maleic 
anhydride)[45, 54] are the most frequently used backbones. DHLA [46, 49-53] and 
cysteamine [44, 45, 47] are mostly used as anchoring group, and polyethylene glycol 
(PEG) [45, 48-50, 52-54] is often used as pendant group to increase water solubility and 
minimize non-specific cellular binding. However, the reported pH stability is still in a 
limited range and short time. For instance, polyPEG QDs were incubated at room 
temperature for 4 h in a pH range of 5-10.5 [48], or for days over a pH range 5.0-9.0 
[205]. In this work, a wide pH range of 2-12 has been tested with as long as 24 h 
incubation time, showing great pH stability and potential to adapt to a more complex 
body environment. Besides, it is reported that SiO2 and PE-PEG coated QDs has 
remarkable stability among pH 1-14 [38], however the pH stability was recorded for only 
1 h and the size of the modified QDs are as large as 40-50 nm. These QDs are good 
candidates for pH sensing, but may not be very suitable for biological application since 
further bioconjuation will undoubtedly increase the overall size. 
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Thirdly, the introduction of reverse micelle can prevent QDs aggregation and help 
keeping good dispersity. This has been demonstrated by the TEM images and the DLS 
analysis. The reason is that the reverse micelles are tiny droplets of water encapsulated by 
the surfactant molecules IGEPAL CO-520 and thus physically separated from the 
cyclohexane oil phase. This water-in-oil microemulsion provides microreactors for QDs 
coating with hydrophilic cysteamine-HA molecules, therefore allows excellent control of 
the particle size, shapes, homogeneity and negligible contamination of the product 
compared with other bulk wet approaches like traditional biphasic exchange method with 
thiol containing molecule and polymers [43, 44]. 
It is notably that HA targets the cell receptor through the carboxyl groups, 
therefore the modification ratio of carboxyl groups on HA is very important. People have 
done a series of work using adipic acid dihydrazide modified HA to conjugate 
commercial carboxyl Quantum Dots for in vivo imaging, and found that lower carboxyl 
modified HA (i.e. 35%, 22%) kept the targeted ability for HA receptors in liver, while 
higher modification ratio (i.e. 50%, 68%) HA will lose much of HA targeting ability 
[196, 197]. In our work, about 42% of the carboxyl group on HA was modified and the 
CD44+ cancer cell targeted imaging test has proved that this ratio still works well for HA 
to keep the targeting ability for receptors. 
3.4 Summary 
In conclusion, we have successfully developed a novel HA-cysteamine polymer 
coated QDs that are water-soluble, and stable for long time and over a large pH range. 
The polymer coated QDs shows great biocompatibility and no significant toxicity. 
Moreover, the HA-cysteamine polymer coated QDs holds CD44+ cancer cell targeting 
ability for breast cancer cell lines. In our work, we only test breast cancer cell lines, but 
we can see the potential of HA-QDs for other CD44+ cancer cell lines. Besides, the 
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carboxyl groups on the polymer also allows for further functionalization and conjugation. 
These HA polymer coated QDs open new possibilities such as for long time single QDs 








Based on the previous work of HA-cystamine polymer coated QDs, the HA 
polymer was further conjugated with DTPA and DOTA for multi-modality MRI/optical 
and PET/optical imaging. The DTPA can conjugate Gd ion thus provides ability for MRI 
imaging and the DOTA unit renders the QDs to have the ability for conjugating Cu ion 
which provides future ability for 64Cu isotope coupling for PET imaging. The resulting 
QDs have great water solubility, and excellent colloidal stability. The biocompatibility to 
NIH/3T3 fibroblast cells and Hela cervical cancer cells were tested. Moreover, CD44+ 
cancer cell targeting ability for cervical cancer cell lines were also tested. This novel HA-
DTPA and HA-DOTA polymer holds the promise for multi-modality imaging, such as 
MRI/optical, PET/optical, SPECT/optical and MRI/PET/SPECT/optical imaging and will 
have an important influence on cancer diagnostics, molecular imaging, and the 
integration of different modality imaging. 
4.1 Background of Multi-modality imaging probes 
4.1.1 Background  
Different imaging techniques have their own unique advantages and inherent 
limitations; therefore, it is unlikely that a single probe can be used for all applications. 
Typically, high-resolution imaging modality has relatively poor sensitivity, while high 
sensitivity imaging technique usually has poor resolution. For example, fluorescence 
imaging can provide high sensitivity, and the ability to have sensitivity for single cells 
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and subcellular imaging, and can achieve multiplex imaging, but lower tissue penetration 
depth. MRI and PET can provide high penetration depth, and they are non-invasive 
imaging techniques. However, PET has a relatively low spatial resolution and the 
sensitivity of MRI is relatively low [122, 189].  
 
 
Figure 4.1. Comparisons of advantages and limitations for each imaging modality (from 
Yan Xing et al. [12]) 
 
In recent years, a variety of imaging modality fusion concepts are very popular 
and multi-modal imaging techniques and equipment has been greatly developed. 
Researchers have learned that different imaging modalities can complement to each other 
and will have a big impact on the bio-medical imaging area. The first fusion of two 
modal PET / CT device was developed in 1998 by Townsend and his colleagues in 
cooperation with Siemens Medical and machine was commercially available in 2001 
[14]. The next dual-modality PET / MRI instrument was also expected to improve patient 
safety and in the imaging capability than PET / CT. Nowadays, PET, CT, SPECT, 
Fluorescence imaging modalities have been fused and developed to 4-modality imaging 
machine [13]. With the emergence and gradual integration enhanced imaging technology, 
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these new tools led to the imaging probe design and development, in order to help multi-
modality imaging equipment to better realizes the advantages of multi-modality imaging. 
 
Figure 4.2. Multi-modality imaging machines (A) Quad-modality imaging system design, 
which consisted of PET, CT, SPECT, and FMI modules. (B) Photograph of quad-
modality imaging prototype system. (from Lu et al [13]) 
 
In the past few years, the research on multi-modal molecular imaging probe has 
made a lot of progress [14]. The imaging method of multi-modal probes will help to 
achieve high resolution, high sensitivity biomedical imaging. To have a more 
comprehensive view of the disease, an ideal situation is to use multi-modality contrast 
agent on multi-modality imaging techniques. An advantage of the multi-modality contrast 
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agent is to avoid multiple injections of contrast agent in the body. What’s more, multi-
modality probes allow the overall optimization of space, time and sensitivity and can 
obtain a variety of information in organ, tissue, cellular and sub-cellular level. For 
example, the research on bimodal contrast agents, optical / MRI contrast agents have 
been studied a lot in recent years. The optical contrast agent allows the detection of 
fluorescence intensity of the cells or sub-cellular level while MRI contrast agents 
typically have a deep tissue penetration property, can reflect physiological differences in 
tissue and organ levels [14]. Thus, these two complementary techniques help to obtain 
information that will allow a more precise diagnosis. 
Although not all imaging applications require multiple imaging modality binds to 
a single probe, a multi-modality imaging probe has many advantages. A multi-modal 
probe can guarantee the same pharmacokinetics and co-localization of different imaging 
modes. Also it avoid using multiple doses of imaging probes to bring a lot of pressure to 
the in vivo blood clearance [14]. One thing should be note is that, due to the different 
sensitivity between different imaging modalities, we cannot simply add all different 
modalities to one molecule, because the required concentration of the contrast agents are 
different among different imaging modes [14].  
Functionalized nanoparticles for enhancing medical diagnostic image contrast has 
been playing an increasingly important role in molecular imaging and is very important. 
Currently the most active areas of research on multi-modality probes are in nano-
materials, which has proved good integration of other imaging modalities to form a multi-
modal imaging probes [7]. The size and nature of the multi-component nanomaterials 
provides an excellent platform that can combine with various imaging modalities. 
Compared with a typical traditional multi-modality small molecular probes, the synthesis 
procedure of some of the of nanoparticles are relatively simple and fast, and does not 
require complex multi-step organic synthesis and allow a modular approach, so that the 
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element replacement for the nanoparticles can be done only by changing simple reagents 
and does not require the entire redesign [14].  
Multi-modality imaging contrast agents can provide a plurality of signals from a 
biological sample, thus greatly improving the visualization of biological processes. The 
combination of optical imaging techniques and MRI may represent a useful imaging 
modality pair for more accurate biomedical detections [22-24], Where MRI or optical 
imaging can be used to track the distribution of the probes in the body. The advantage of 
MRI is its high anatomy spatial resolution, but its sensitivity is not good enough, 
especially for the tiny tumors. While fluorescence imaging has high sensitivity, and the 
instruments nowadays can detect very little photons and present images on the computer 
screen. Shorter wavelength light cannot penetrate to deeper tissue, which limits its 
biological applications. However, the near infrared light can penetrate to relatively deep 
tissue. Therefore, by combining MRI and fluorescence imaging together, a multimodal 
imaging probe will has the advantages of high sensitivity and high spatial resolution, so 
as to enhance the ability of recognition and diagnosis of tumors. 
4.1.2 Multi-modality QDs probes 
The advantages of quantum dot have made them a good substitute for 
fluorescence imaging because it can diagnose diseases and other applications at the 
cellular level to achieve high sensitivity, high spatial resolution, and target-specific real-
time imaging. However, fluorescence imaging technology also has its own drawbacks, 
such as low tissue penetration depth and biological auto-fluorescence, which limits its 
application in imaging deep tissue. Therefore, they are widely studied in developing 
multi-modal probes, such as combining PET or MRI [21]. A main approach for 
synthesizing multi-modality quantum dots can be classified as a conjugation method, 
such as gadolinium and other molecules attached to the QDs surface via chemical 
connection. A typical approach is to attach agents such as DOTA and DTPA to the 
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surface of the quantum dot to chelate PET- or MRI active molecules [55-57, 143, 172-
176]. The second method is a core / shell structure, other molecules are comprised in an 
additional layer to coat QDs [58, 59]. The third way is by doping the appropriate 
molecules or atoms such as Mn into the QD core [22, 60]. 
QDs conjugates 
The most direct method of modifying quantum dots is by using bifunctional 
chemical crosslinkers to attach two different molecules to each other, typically functional 
groups such as amine, thiol or carboxyl group, followed by reaction of the crosslinking 
agent for a given functional group for specifically connection [206]. A typical approach is 
to attach agents such as DOTA and DTPA to the surface of the quantum dot to chelate 
PET- or MRI active molecules [189]. The traditional method through coupling chemistry 
using succinimidyl ester derivative has been widely used for connecting gadolinium (III) 
or 64Cu to the amino group on quantum dot surface. In this way, DOTA and DTPA have 
been coupled to the CdTe / ZnS quantum dots [207] CdSe/ZnS, and glutathione-coupled 
CdSeTe/CdS QDs. 
 
Figure 4.3. Synthesis of dual-function PET/NIRF probe DOTA–QD–RGD through 
Chelator coupling to surface of CdTe nanoparticles. (From Louie [14]).  
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  A uridine-based dual-modality probe based on quantum dots (QDs) has been 
reported [208]. The Gd3+-QDs was synthesized through complex procedures. The Gd3+-
QD can penetrate the cell surface and can be delivered into the RAW 264.7 cells. The 
Gd3+-QD enables high-performance MR and fluorescence imaging. This work provides 
possibilities for QDs based optical/MR imaging, but the synthesis is complex and the 
coating material cannot provide targeted ability. 
In order to limit the intrinsic toxicity of QDs constructed from heavy metals, 
Stasiuk et al. used InP/ZnS quantum dots with an emission wavelength at around 620 nm 
which were direct conjugated with gadolinium chelates containing single thiol or dithiol 
[209]. Another work by Erogbogbo et al. used silicon QDs which is composed of a 
PEGylated micelle, with hydrophobic Silicon QDs in the core, covalently bound to 
DOTA-chelated Gd3+, with dynamic light scattering radius of 85 nm [210]. In this work, 
after the macrophages cell uptake, the probes maintain their optical properties within the 
intracellular environment. However, only in vitro work was done and tumor-targeted 
study has not been done.  
Lipid-Coated dual-modality QDs 
Another method for making dual-modality QDs is to introduce paramagnetic ions 
to the coating lipid shell of the QDs where Gd chelates with lipids are inserted into the 
lipid coating layer to render MRI functionality [15]. Mulder group have done a lot of 
work using this typical configuration for different biomedical applications [211-215]. The 
process was done through evaporation of the mixture of QDs and paramagnetic lipids, as 
shown in Figure 4.4 [216]. The properties of the particles are similar to liposomes and 
can be synthesized in a similar size ranges with the QDs which are usually smaller than 
10 nm [214]. The size and use of stealth coatings such as PEG can both facilitate to 




Figure 4.4. Synthesis of lipid-coated multi modality QDs (form Louie [15]) 
 
Doped QDs 
The third method is by doping the appropriate molecules to QDs. Because the 
QDs are really small, doping into QDs are very challenging, but still has been studied a 
lot. The QDs has been doped with transition metals, and the properties are characterized 
[217-222]. For example, Mn has been doped into II-VI quantum dots such as ZnSe [223], 
ZnS [224], CdSe [225], and into III-V systems such as InP [226]. The doped QDs 
materials has been investigated for multimodal imaging applications.  
There are some challenges for directly doping into the QDs, because many 
introduced dopants of impurities will quench the luminescence efficiency of the QDs. 
The quenching is in a concentration dependent way, therefore the improvement of the 
MR contrast properties will degrade the optical imaging ability [227]. In order to avoid 
this problem, researchers have studied many ways to incorporate the paramagnetic ions 
into the outer coating shell rather than the core to keep the luminescent efficiency. Most 
quantum dots for biological applications are core/shell structure where the core is coated 
with a shell of different materials [228]. The shell helps to protect the core from 
degradation and also improve the surface passivation thus increase the luminescence 
efficiency. For example, Cd-based QDs (CdSe, CdS, etc.) are usually coated with ZnS 
shell to prevent the release of toxic Cd ions if the core is degraded. The concept of shell 
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coatings provide a good platform of multi-modality probes, for each layer can have 
another functionality, and a lot of work were designed and reported. 
The fabrication of Gd-doped CdTe quantum dots (Gd:CdTe QDs) as an agent for 
dual-modality MRI/ optical imaging was shown in Figure 4.5. A facile one-pot aqueous 
approach was used and the QDs are synthesized at room temperature with an ultrasmall 
particle size. Further conjugation with the folic acid renders the QDs targeting ability and 
successfully labelled live HepG2 cells for targeted cellular imaging [16]. 
 
 
Figure 4.5. Schematic shown for the synthesis of the Gd:CdTe QDs and their surface 
function with Folic acid. (from Zhang et.al [16]) 
 
In another work by Dr. Mingyuan Gao’s group, Cd-free CuInS2@ZnS:Mn QDs 
were synthesized for dual-modality fluorescence and MRI imaging of tumors in vivo 
[22]. Those QDs has a Zn gradient CuInS2 core and a ZnS shell and the Mn ions were 
incorporated into the ZnS shell in order to balance the optical and magnetic properties of 
the QDs. The QDs were further PEGylated through ligand exchange by using DHLA-
PEG ligand. The resulting QDs showed 7000 times lower cytotoxicity than the CdTe 
QDs and experiments on fluorescence and MR imaging of tumors showed that both the 
subcutaneous and the intraperitoneal tumor can be visualized for in vivo imaging.  
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Dual-Targeting and Dual-Modality in vivo cancer imaging with Quantum Dots  
Except for dual-modality imaging probes, dual-targeting probes was another trend 
that was studied. Recently a dual receptor targeting dual-modality PET/near-infrared 
fluorescence (NIRF) probe was developed for a more accurate evaluation of tumor-
targeted efficacy of QDs [17]. In this work, the QDs were modified with beta-Glu-RGD-
BBN (BBN is bombesin) peptides and labeled with F-18 via the 4-nitrophenyl-2-F-18-
fluoropropionate prosthetic group. As shown in Figure 4.6, the structure of the multiplex 
modifying multi-functional QD probe was on the left and structure of single modified 
multi-functional QDs probe was in the middle, and strategy for enhancing synergistic 
binding of the hetero-dimeric multi-functional QDs probe was on the right. The 
functionalized QD probe showed a great promise as a universal dual-targeting probe for 
in vivo detection of tumors and opens up a new strategy for multi-targeting multi-
modality QD probes for improved tumor-targeting efficacy. 
 
 
Figure 4.6. Schematic illustration of functionalized QD probe for in vivo cancer dual-
targeting and dual-modality imaging (from Kongzhen Hu et al. [17]) 
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Summary 
Combining modalities of different instruments and in different probes have the 
advantages and benefits, but there is no one is the best approach for all problems. The 
clinical applications for multi-modality probes still need time to establish for not all 
applications benefits from an all-in-one probe. Therefore, to identify the diagnostic and 
therapeutic targets that have the most to gain from common probe is still a challenge that 
will aid in increase of the acceptance of multi-modality imaging probes. What’s more, the 
collaboration between biologists, chemists, and clinicians is very important in order to 
adapt biologically incompatible probes with imaging properties for the realistic uses. 
Greater cross communication and multi-modality cross communication will be crucial for 
the development of new probes especially for novel nanotechnology platforms. Another 
thing that need to notice is that some modalities such as PET and MRI have different 
sensitivities, therefore multi-modality probes will require a lot of low-sensitivity probes 
which increase probe size comparing to the high sensitivity probe, in order to fulfill the 
concentration requirements for each modality. In an ideal situation, fusing probes of 
different functions should not reduce each probe’s individual effectiveness [15]. 
4.2 HA-DTPA-Gd QDs for dual-modality optical/MRI imaging 
4.2.1 Materials and Methods 
Materials 
Sodium hyaluronate with MW of 6300 was purchased from Lifecore (USA). 
Cystamine dihydrochloride, dithiothreitol (DTT), IGEPAL CO-520, 
tetramethylammonium hydroxide (TMAH), diethylene triamine pentaacetic acid (DTPA) 
were purchased from Sigma-Aldrich. NIR QDs were purchased from Invitrogen. EDC 
and sulfo-NHS were purchased from Pierce. GdCl3 were purchased from Aladin. Tetra-
azacyclododecanetetra-acetic acid (DOTA) was purchased from STREM chemicals. Dry 
DMSO was provided by J&K Scientific. Cyclohexane, Methanol, Ethanol and other 
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solvent were purchased from Sinopharm Chemical Reagent Beijing. Dialysis tube 
(MWCO 1000) was purchased from Spectrum Labs. UV–Vis absorption spectra were 
obtained using a UV-2550 UV-vis spectrophotometer (Shimadzu). The fluorescence 
spectrum was recorded on a Nanolog FL3-2iHR (HORIBA JOBIN). The structural 
details of the nanoparticles were analyzed by the HRTEM method using a JEM-2100F at 
Peking University. NMR spectrums were performed on a 400Hz NMR machine at the 
NMR imaging Center of Peking University. Gadolinium and copper contents were 
determined on an inductive coupled plasma-optical emission spectrometry (PROFILE 
SPEC, Leeman Labs, USA). MRI images are acquired on a GE Discovery MR 750 3.0T 
machine with a T/R Animal coil by Magtron-35mm using SE series. 
Methods 
Synthesis of HA-cystamine-DTPA-Gd polymer 
As shown in Figure 4.7, the synthesis of HA-cysteamine-DTPA-Gd polymer 
involves four steps: synthesis of HA-cystamine polymer, DTPA conjugation to the HA-
cystamine polymer, Gd coupling and reduction of the disulfide bond of cystamine by 
DTT.  
Typically, sodium hyaluronate with average MW of 6276 was dissolved in PBS to 
about 10 mg/ml, then 17 molar excess of EDC, and final concentration of 5mM sulfo-
NHS were added to the HA sodium salt solution. The solution was stirred for 15min to 
activate the carboxyl groups on HA polymer. Then 30 molar excess of cystamine 
dihydrochloride in PBS were added, and the mixture was kept reacting at room 
temperature for 24 h. The HA-cystamine product was purified by dialysis against pure 
water using dialysis tube (molecular weight cut-off, 1kDa) for 2 days and lyophilized to 
get the dry HA-cystamine product. The HA-cystamine conjugation was confirmed by 1H 




Figure 4.7. Synthesis routes of HA-DTPA-Gd polymer  
 












 Hyaluronic acid 
sodium salt 1 39.8 6276 250 23 in PBS 
COOH 17 677.2         
EDC 30 1195.1 191.7 229.1 1   
sulfo-NHS   125 217.13 27.1 1   
Cystamine 
dihydrochloride 30 1195.0 225.2 269.1 0   
          25 in PBS 
 
 
According to previously reported method [229, 230], DTPA was conjugated to 
the HA backbone by the formation of ester bonds between the carboxyl group in DTPA 
and the hydroxyl group in the HA backbone. Typically, 40 molar excess of DTPA and 
HA-cystamine were dissolved in 50 ml of anhydrous dimethyl sulfoxide and protected 
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with a drying tube containing calcium chloride inside. The mixture was stirred for 24 h at 
room temperature, and after the reaction, 25 ml of pure water was slowly added to the 
solution. The resulting solution was placed in a dialysis bag (molecular weight cut-off, 
1kDa) and dialyzed against pure water for 2 days. The dialysis product was lyophilized 
and the HA-cysteamine-DTPA product was obtained as a powder.  
The conjugation of DTPA to HA was confirmed via fourier transform infrared 
spectrometry (FT-IR) on a VECTOR22 (Bruker, Germany). Spectra was recorded on 
KBr plates over the range 4000~400 cm-1 at a wavenumber resolution of 1 cm-1. To 
determine the amount of DTPA that was conjugated to HA, NMR was also conducted on 
a 400MHz NMR machine. 









(ml)   
HA-cystamine 1 9.2 6276 57.8 50 in DMSO 
DTPA 40 368.4 393.35 144.9     
 
 
Subsequently, for Gd coupling, 50 molar excess of GdCl3·6H2O and HA-
cysteamine-DTPA polymer were dissolved in 8 ml of water and shaked for 24 h at room 
temperature and then dialyzed in a dialysis bag (molecular weight cutoff, 1 kDa) against 
pure water for 1 day.  
 
Table 4.3. Typical amount for Gd coupling with HA-cystamine-DTPA polymer. 










1 9.2 6276 57.8 8 in water 




Finally, for DTT reduction of the disulfide bond on cystamine, DTT of a final 
concentration of 80mM was added and the whole solution was shaked for 24 h. After 
dialyzing, 5~10 mg DTT was added to the solution to protect the free thiol groups. After 
lyophilizing, the HA-Gd polymer was collected.  
Gadolinium contents were estimated on an inductive coupled plasma-optical 
emission spectrometry (ICP-AES). For the ICP-AES sample preparation, the HA-Gd 
polymer was digested by adding 3.5mg polymer to 5ml HNO3, and incubates overnight. 
On the 2nd day, 2ml perchloric acid was added and the mixture was heated slowly to 
170°C for 1.5h. Finally pure water was added to 10 ml. Gadolinium contents were 
determined on an inductive coupled plasma-optical emission spectrometry (PROFILE 
SPEC, Leeman Labs, USA). 
QDs coating with of HA-DTPA-Gd polymer and characterization 
NIR Organic (CdSeTe) ZnS QDs of 780 nm emission wavelength were purchased 
from invitrogen. When encapsulating QDs with HA-DTPA-Gd polymer, a modified 
reverse micelle method was used [94, 124, 202]. Typically, 200µl of 1µM QDs in decane 
were diluted with 4.5 ml cyclohexane and 0.5 ml IGEPAL CO-520 was added to the 
solution. Then 3.5~4 mg of HA-DTPA-Gd polymer in 50 µl water was added to form 
reverse micelle. 50 µl of 0.1M Tetramethylammonium Hydroxide (TMAH) in methanol 
was also added as a catalyst. The mixture was votexed for 1 min, and shaked for 60 min. 
After reaction, 1 ml ethanol was added and the solution was centrifuged at 6000g for 5 
min to precipitate the HA polymer-coated QDs. The pellets were washed with additional 
ethanol for 3 times and washed with water once and finally re-dispersed in water. After 
centrifuging the QDs solution at 5000 g for 5 min to get rid of the undissolved parts, the 
supernatant which contains the HA polymer-coated QDs was purified using a 0.45 µm 
syringe filter. 
For characterization, the UV-vis absorption spectrum was recorded on a UV-2550 
UV-vis spectrophotometer (Shimadzu). The fluorescence spectrum was recorded on a 
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Nanolog FL3-2iHR (HORIBA JOBIN). The structural details of the nanoparticles were 
analyzed by the HRTEM using a JEM-2100F under the help of Dr. Jia at College of 
Chemistry and Molecular Engineering, Peking University. This machine was equipped 
with a field emission gun, ultra-high resolution pole piece, and ultrathin window JEOL 
detector. An OSIS CANTEGA CCD camera was used to obtain the HRTEM images. The 
gadolinium contents were determined on an inductive coupled plasma-optical emission 
spectrometry (PROFILE SPEC, Leeman Labs, USA) by digesting QDs with HNO3 and 
perchloric acid. 
Relaxation rate measurements of the HA-Gd QDs 
The T1 relaxitivity of HA-GD QDs was compared with Gd-DTPA solution of the 
same Gd concentration. The test was performed with GE Discovery MR 750 3.0T 
machine. The T1 contrast intensities of the HA-Gd QDs and Gd-DTPA solution were 
scanned at 0.2, 0.1, 0.05, 0.02, 0.01 and 0.005 mM of Gd concentrations. Typically, 500 
µl of HA-Gd QDs and Gd-DTPA solution at different concentrations were put in each 
1.5ml Eppendorf tube, and placed in a plastic box containing pure water. A head and 
neck unite coil of the MRI machine was used to hold the box and T1-weighted MR 
images was collected at different repetition time. The specific parameters are as follows: 
echo time (TE) = 9 ms, repetition time (TR) = 100, 200, 300, 600, 900, 1200, 1500 ms. 
Cell viability test 
Hela cervical cancer cell line was cultured in DMEM with 10 % FBS and 1 % 
streptomycin and penicillin antibiotics. On the first day, cells were seeded on a 96-well 
plate at 5000 cells/well. After 24 h culture, HA-Gd polymer-coated QDs were added to 
the 1, 4 and 8 h incubation time group with the final concentrations of 1, 5 and 10 nM. 
For the control group, cells of the same number were seeded but no QDs were added. 
This is regarded as 100 % cell viability. A blank control with only cell culture medium in 
the well was regarded as 0 % cell viability. Experiments were quintuplicated. After 
incubation with QDs, 10 µl Cell Counting Kit-8 solution was added to each well. 
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Following incubation with cells at 37 °C for 3 h, the absorbance at 450 nm was measured 
by a plate reader. 
In vitro cell targeted imaging  
CD44+ cervical cancer Hela cells were used for targeted imaging and NIH/3T3 
fibroblast cell was used as a negative control. The cells were cultured in DMEM with 
10% FBS and 1 % streptomycin and penicillin antibiotics. Cells were plated on an 8-well 
chamber slide at 10k cell/well in 400ul culture medium. After 24 h growth, the medium 
was aspirated and cells were washed with 1X PBS buffer and then fixed with 200 µl 4 % 
formaldehyde and 0.25 % Triton X-100 in PBS for each well. After 15 min, cells were 
washed with PBS for 5 min, three times. After fixation, 160 µl blocking buffer of 5 % 
bovine serum albumin (BSA) in PBS was added to each well and incubated for 1h at RT. 
Then blocking buffer was aspirated and each well was washed with PBS three times for 5 
min each. For QDs coating, 100 µl HA polymer-coated QDs were added to each well, 
with final concentrations of 5nM and 20 nM in PBS. After 1 h incubation, the QDs was 
aspirated and washed with PBS for 3 times, 5 min each. The slides were mounted with 
anti-fade mounting media containing DAPI. The slides were imaged under Leica 
DMI3000B microscope. 
In vivo Tumor-targeted fluorescence imaging 
For the in vivo fluorescence imaging experiment, cervical cancer Hela cells was 
used to build the tumor model. Female “Balb/c nude” mice of six weeks are used as the 
experimental models. Tumors were created by subcutaneous injection of 5×106 Hela cells 
in 100 µL PBS buffer onto the back of right shoulder of each mouse. Tumors grew to a 
suitable size at the injection sites 6 weeks later. Before imaging, each mouse was subject 
to isofluorane anesthesia and placed in the animal bed in the right position with the 
anesthesia. HA-Gd QDs with an emission wavelength of 780 nm conjugates were 
prepared and purified with 0.2µm syringe filter before injection. 200µl of 50nM HA-Gd 
QDs were administered to the nude tumor bearing mice by tail-vein injection. 
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The fluorescence of injected HA-Gd QDs was captured with a luminescent image 
analyzer before and after injection. An animal fluorescence imaging system was used to 
take the fluorescence images, which contains a tungsten halogen-based excitation 
module, an adjustable animal holder, a high sensitivity CCD camera (iKon 934 M, 
Andor) detection module and a gas anesthesia component. High-resolution images 
(512×512 pixels) were taken using GFP filter (FF01-466/40-25) for excitation and Cy7 
filter (FF02-809/81-25) for emission. The raw data was acquired under the control of 
baseline clamp and processed by Andor SOLIS software. The images were processed by 
ImageJ.  
In vivo Tumor-targeted MRI imaging 
For in vivo MRI imaging, the animal model was the same as for the fluorescence 
imaging. Female “Balb/c nude” Hela tumor bearing mice was used. The tumor-bearing 
mice are obtained by injecting Hela cells into their right back without any other 
treatment. After the tumors formed at the injection sites, mice were taken for MRI 
imaging. Before imaging, the mouse was injected with 10% chloralhydrate anesthesia for 
100 µl / 25g mouse and placed in the animal bed in the ventral position. Then, HA-Gd 
QDs conjugates were prepared and purified with 0.2 µm syringe filter before injection. 
200µl of 50nM QDs were administered to the nude tumor bearing mice by tail-vein 
injection. MRI images are acquired before and after the injection of the HA-Gd QDs 
contrast agents, on a GE Discovery MR 750 3.0T machine with a T/R Animal coil by 
Magtron-35mm using SE series. The TR was set to be 400 and TE was 12. 
4.2.2 Results and Discussions 
Characterization of HA-cystamine-DTPA polymer 
The synthesis of HA-cysteamine-DTPA-Gd polymer involves four steps: 
synthesis of HA-cystamine polymer, DTPA conjugation to the HA-cystamine polymer, 
Gd coupling and reduction of the disulfide bond of cystamine by DTT. 
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For the HA-cystamine polymer conjugate DTPA, from the FT-IR image of HA-
cystamine-DTPA (Figure 4.8), the peak at 1730cm-1 which represents the C=O formation 
is a strong sign that DTPA was successfully conjugated to the HA backbone.  
 
 
Figure 4.8.  FT-IR image of HA and HA-cystamine-DTPA  
 
The HA-cystamine conjugation was confirmed by NMR.  As shown in Figure 4.9, 
the comparison of HA and HA-cystamine, the peak at around 2.85 ppm and 2.95 ppm 
which is the cystamine was shown, which proved successful conjugation of cystamine to 
HA polymer. The amount of cystamine and DTPA that was conjugated to HA can be 
calculated from the integration of the corresponding part on the NMR curve. After 
calculation, there were ~6 cystamine on each HA polymer. 
Quantitative characterization of DTPA that was conjugated to HA-cystamine 
polymer was also confirmed by NMR. The NMR curve was shown in Figure 4.9, and the 
NMR prediction by chemdraw was shown in Figure 4.10. The circles of the same color 
represent the corresponded group. The amount of DTPA that was conjugated to HA can 
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be calculated from the integration of the corresponding part on the NMR curve. After 
calculation, there were 1 DTPA on every 2 HA polymer. 
 
 
Figure 4.9  NMR image of HA-cystamine-DTPA  
 
 
Figure 4.10.  NMR prediction by Chemdraw of HA-cystamine-DTPA 
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Characterization of HA-Gd polymer coated QDs 
  UV-absorption and Fluorescence curve before and after HA-Gd polymer coating 
were shown in Figure 4.11. The QDs absorption and emission curve after HA-Gd 
polymer coating keeps the same shape as before coating, thus indicates a good stability of 
the HA-Gd polymer coated QDs. 
 
Figure 4.11. UV-absorption and Fluorescence image of QDs and HA-QDs  
 
A typical TEM image of NIR QDs in decane was shown in Figure 4.12 A, where 
the as-prepared HA-Gd QDs was shown in figure B. The HA-Gd QDs exhibited a 
triangle-like geometry with a diameter of ∼10 nm, and were highly dispersible in water. 
The surface conjugation of QDs with DTPA and further Gd3+ chelation did not obviously 
affect the morphology of QDs, as evidenced by the TEM images. 
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Figure 4.12. TEM figures of QDs in decane (A) and HA-Gd QDs (B)  
 
Gd content determination of HA-DTPA Gd QDs by ICP-AES 
200 µl HA-DTPA Gd QDs were used for ICP-AES. Typically, 200 µl QDs were 
diluted with 5ml HNO3 and stay overnight. The second day 2 ml perchloric acid were 
added and the whole solution was heated to 170 °C for 1.5h. Finally, the solution was 
cooled to room temperature and pure water was added to 10ml for ICP-AES. After 
running ICP-AES, the Gd content in solution is 0.781 µg/ml. therefore, there were total 
7.81µg Gd in 10ml solution. Namely, in 200 µl QDs, the Gd content is 7.81µg 
/(157.25g/mol) =0.0497 µmol = 49.7 nmol.  
The concentration of Gd is 49.7nmol / 200µl = 2.485*10-4 mol/L=248.5 µM. The 
concentration of QDs was determined by UV-vis absorption, which is 123.23 nM. 
Therefore, there were 248.5 / 123.23 * 1000 = 2016 Gd ions per QD. 
Calculation of longitudinal relaxation rate 
T1-weighted MR images of the HA-Gd QDs according to the Gd concentration 
are presented in Figure 4.13. As the Gd concentration increased, the MR signals also 
strengthened, which can be seen by the brightness.  
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Figure 4.13. T1-weighted MR images of HA-Gd QDs and DTPA-Gd solution at different 
TE value  
 
According to the T1 calculation equation: 
SSE (TR,TE) = N (H )[1- 2e
-(TR-TE 2) T1 + e-(TR T1) ]e-(TE T 2)               (4.1) 
SE refers to the Spin Echo, TR refers to Time of Repetition and TE refers to Time 
of Echo. For the calculation of T1, We can use any two SSE value such as S1 and S2, by 




1− 2e−(TR1−TE /2)/T1 + e−(TR1/T1)
1− 2e−(TR2−TE /2)/T1 + e−(TR2 /T1)
                          (4.2) 
Using the corresponding TR1 and TR2, we can get different T1 value. By 
calculating the average of T1, we can get T1 value at different concentrations of Gd. 
Through programing on Matlab, different T1 value at different concentration was 
calculated.  The code was as the following: 
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Figure 4.14. The matlab code used for calculating the T1 value at different concentrations 
of Gd.  
 
After running the program, a curve of y will be plotted and the minimum value at 
the valley will be corresponded T1 value. By calculating the average of different T1 
value, we can get T1 value of different concentration. 
 
Figure 4.15. The typical curve for T1 value calculation 
Quantitative analysis on Origin software showed a linear relationship between the 
proton longitudinal relaxation rate (1/T1) and Gd concentration. The linearity between T1 
relaxivity (r1) of the HA-QDs and Gd concentration indicates that Gd3+ was successfully 
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chelated into the DTPA ligand on HA shell of the QDs. The specific relaxivity (r1) of 
HA-Gd QDs was 5 mM-1s-1, which is slightly higher than the DTPA-Gd solution. 
 
Figure 4.16. The proton longitudinal relaxation rate (1/T1) according to the Gd 
concentration. 
 
Biocompatibility test of HA-Gd QDs on Hela cell lines 
The cytotoxicity of HA-Gd QDs was examined in cervical cancer Hela cells. QDs 
of different final concentrations of 1, 5, 10 nM were incubated with the cells for 1, 4 and 
8 h. The experiments were performed in quintuplicated and T test was performed for each 
group comparing to the control group. As shown in Figure 4.17, no significant 
cytotoxicity was observed at all concentration and incubation time groups and the cell 
viability remains over 80 %. This result has proved great biocompatibility for the HA-Gd 
QDs, and shows the potential for in vivo applications in the future.  
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Figure 4.17. Cell viability test of Hela cells.  
 
In vitro cell targeted imaging 
CD44+ Hela cell lines were used for targeted imaging and NIH/3T3 cell line was 
used as a negative control. QDs with different final concentrations of 5 nM and 20 nM 
have been tested, and shown in Figure 4.18. Obviously, strong fluorescence on Hela cell 
lines was observed but no fluorescence on NIH/3T3 cell line can be seen. This result not 
only demonstrates the HA-Gd polymer coated QDs still remains the targeted ability for 
CD44+ cancer cells, but also indicates very little non-specific cellular binding for 
NIH/3T3 cell.  
In vivo Tumor-targeted fluorescence imaging 
The HA-Gd QDs was prepared with the final concentration of 50 nM in PBS 
buffer and administered intravenous injection (200 µL per mouse) into the nude mice 
bearing subcutaneous Hela tumors. An animal FL imaging system was used to take the 
fluorescence images. We set the GFP excitation filter (FF01-466/40-25) and the Cy7 
emission filter (FF02-809/81-25) to take the fluorescence images.  The pictures of HA-
Gd QDs solution in tube before injection were shown in Figure 4.19. Figure 4.19 (A) 
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shows the bright field image while B is the fluorescence image. Figure 4.19 (C) was the 
overlay of the bright field and fluorescence images. 
 
 




Figure 4.19. The HA-Gd QDs that was used to inject the mouse. (A) Bright field image. 
(B) Fluorescence image. (C) Overlay of the bright field and fluorescence images. 
 
As shown in Figure 4.20, a series of in vivo images detected by the animal 
fluorescence imaging system at different time was taken. The fluorescent background as 
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a control prior to injection was collected first (Fig 4.20 (A)). After HA-Gd QDs was 
injected through the tail vein, fluorescence images of the mouse were collected at 1 h, 2 
h, 3 h and 6 h, respectively. The images indicated that fluorescence signal was observed 
in the tumor after 1 h (Figure 4.20 (B)). During the 2 h time intervals, there was an 
obvious increase area of fluorescence signal in tumor site, indicating highly specific 
tumor targeting of HA-Gd QDs. After 3 h, the fluorescence showed slightly decrease. By 
reviewing the literatures of QDs in vivo tumor-targeted imaging, most of the QDs started 
to accumulate at the tumor sites around 1-2 hours [6, 11, 197, 231-237], which coincide 
with our results.  
 
Figure 4.20. In vivo fluorescence imaging of Hela tumor-bearing mice injected with HA-
Gd QDs. (A) before injection (B) 1 h (C) 2 h (D) 3 h (E) 6 h after HA-Gd QDs was 
injected. The figures are the merged images of bright field and fluorescence images. All 
of the images were taken under the same condition. 
 
To verify the information collected from the in vivo fluorescence images, the 
mouse was sacrificed after 24 hours. The tumor and organs (liver, spleen, heart, lung and 
kidney) of the mouse were taken out and the fluorescence image was acquired, which 
was shown in Figure 4.21. Fluorescence intensity in tumor tissues and liver was stronger 
than other tissues (heart, kidney, spleen and lung). 
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Figure 4.21. The fluorescence image of the tumor and organs of the mouse. (A) Photo to 
show the organs and tumor. (B) Bright field image. (C) Fluorescence image. (D) Overlay 
of the bright field and fluorescence images. 
 
In vivo Tumor-targeted MRI imaging 
The in vivo MRI imaging was performed in mice bearing transplanted Hela 
tumor. The HA-Gd QDs (50nM QDs concentration, 100µM Gd concentration, 200 µL) 
was injected into mice through tail vein. The MR images were acquired before injection 
and at 1 h after injection as illustrated in Figure 4.22. The positions of tumor were 
indicated by arrow. A significant contrast enhancement of the whole body and tumor 
tissue was observed at 1 h after injection on the MRI image. These in vivo experiments 
showed that the HA-Gd conjugated QDs selectively target CD44 overexpressed tumor 
after systemic administration and are sufficient to contrast the CD44 expression in tumor 
lesions using both T1 MRI sequence and Fluorescence modalities. 
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Figure 4.22. T1-weighted MR images of the mice bearing Hela tumor (as indicated by 
arrow) following tail vein injection of HA-Gd QDs obtained at 0 h (before injection, 
Figure A) and 1 h (Figure B) after injection. 
 
4.2.3 Summary 
As a summary, we have successfully conjugated HA-cysteamine polymer with 
DTPA via the formation of ester bonds between the carboxyl group in DTPA and the 
hydroxyl group in the HA backbone and the HA-cystamine DTPA polymer was used to 
coat NIR QDs. The QDs has the binding ability of Gd through the DTPA group. The Gd 
ion conjugation provides ability for MRI imaging and the calculated longitudinal 
relaxation rate is comparable with DTPA-Gd solution. Therefore, dual-modality 
MRI/optical imaging probes can be realized through this novel method. The resulting 
QDs have great water solubility, and excellent colloidal stability and also show great 
biocompatibility and no significant toxicity to NIH/3T3 fibroblast cells and Hela cervical 
cancer cells. Moreover, the HA polymer-coated QDs hold CD44+ cancer cell targeting 
ability for cervical cancer cell lines. Besides, the carboxyl groups on the polymer 
backbone also allow for further functionalization and conjugation with other targeting 
probes like ligands or antibodies. Therefore, the HA-DTPA Gd polymer coated QDs can 
be applied for dual-modality MRI/optical imaging and can be used for variety of 
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biomarkers detection such as multi- plexed biomarker staining and for in vivo molecular 
imaging as well as targeted drug delivery. 
4.3 HA-DOTA-Cu QDs for dual-modality optical/PET imaging 
4.3.1 Materials and Methods 
Materials 
Sodium hyaluronate with MW of 6300 was purchased from Lifecore (USA). 
Cystamine dihydrochloride, dithiothreitol (DTT), IGEPAL CO-520, 
tetramethylammonium hydroxide (TMAH) were purchased from Sigma-Aldrich. NIR 
QDs were purchased from Invitrogen. EDC and sulfo-NHS were purchased from Pierce. 
tetra-azacyclododecanetetra-acetic acid (DOTA) were purchased from STREM 
chemicals. dry DMSO were provided by J&K Scientific. Cyclohexane, Methanol, 
Ethanol and other solvent were purchased from Sinopharm Chemical Reagent Beijing. 
Dialysis tube (MWCO 1000) was purchased from Spectrum Labs. UV–Vis absorption 
spectra were obtained using a UV-2550 UV-vis spectrophotometer (Shimadzu). The 
fluorescence spectrum was recorded on a Nanolog FL3-2iHR (HORIBA JOBIN). The 
structural details of the nanoparticles were analyzed by the HRTEM method using a 
JEM-2100F at Peking University. NMR spectrums were performed on a 400Hz NMR 
machine at the NMR imaging center of Peking University. Copper contents were 
estimated on an inductive coupled plasma-optical emission spectrometry (PROFILE 
SPEC, Leeman Labs, USA).  
Methods 
Synthesis of HA-cystamine-DOTA polymer 
As shown in Figure 4.23, the synthesis of HA-cysteamine-DOTA polymer 
involves three steps: synthesis of HA-cystamine polymer, DOTA conjugation to the HA-
cystamine polymer and DTT reduction of the disulfide bond.  
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Figure 4.23. Synthesis routes of HA-DOTA polymer  
 
Typically, sodium hyaluronate with average MW of 6276 was dissolved in PBS to 
about 10 mg/ml, then 17 molar excess of EDC, and final concentration of 5mM sulfo-
NHS were added to the HA sodium salt solution. The solution was stirred for 15min to 
activate the carboxyl groups on HA polymer. Then 30 molar excess of cystamine 
dihydrochloride in PBS were added, and the mixture was kept reacting at room 
temperature for 24 h. The HA-cystamine product was purified by dialysis against pure 
water using dialysis tube (molecular weight cut-off, 1kDa) for 2 days and lyophilized to 
get the dry HA-cystamine product. The HA-cystamine conjugation was confirmed by 1H 




Table 4.4. Typical amount for HA-cystamine synthesis. 









sodium salt 1 39.8 6276 250 23 in PBS 
COOH 17 677.2     EDC 30 1195.0 191.7 229.1 1  sulfo-NHS  125 217.13 27.1 1  Cystamine 
dihydrochloride 30 1195.0 225.2 269.1 0  
     25 in PBS  
 
 
According to previously reported method [229, 230], DOTA was conjugated to 
the HA backbone by the formation of ester bonds between the carboxyl group in DOTA 
and the hydroxyl group in the HA backbone. Typically, 40 molar excess of DOTA and 
HA-cystamine were dissolved in 50 ml of anhydrous dimethyl sulfoxide and protected 
with a drying tube containing calcium chloride inside. The mixture was stirred for 24 h at 
room temperature, and after the reaction, 25 ml of pure water was slowly added to the 
solution. The resulting solution was placed in a dialysis bag (molecular weight cut-off, 
1kDa) and dialyzed against pure water for 2 days. The dialysis product was lyophilized 
and the HA-cysteamine-DOTA product was obtained as a powder.  
The conjugation of DOTA to HA was confirmed via fourier transform infrared 
spectrometry (FT-IR) on a VECTOR22 (Bruker, Germany). Spectra was recorded on 
KBr plates over the range 4000~400 cm-1 at a wavenumber resolution of 1 cm-1. To 
determine the amount of DOTA that was conjugated to HA, NMR was also conducted on 





Table 4.5. Typical amount for HA-cystamine conjugating DOTA. 









cystamine 1 7.97 6276 50 50 in DMSO 
DOTA 40 318.7 404.42 128.9     
 
Next for DTT reduction of the disulfide bond on cystamine, DTT of a final 
concentration of 80mM was added and the whole solution was shaked for 24 h. After 
dialyzing against water through 1000 MWCO tube for 1 day, 5~10 mg DTT was added to 
the solution to protect the free thiol groups. After lyophilizing, the HA-cystamine-DOTA 
polymer was collected as powder.  
HA-DOTA polymer for Cu coupling and QDs coating 
As HA-DOTA polymer will be used for isotope Cu coupling, so Cu coupling and 
QDs coating were finished in one step in order to reduce the time for purifying the QDs. 
Typically, 1mg HA-DOTA polymer were conjugated with 10 µl CuCl2 (10 mg/ml in 
water) and 40 µl H2O solution for 1h (37°C). Then the QDs were coated with the HA-
DOTA Cu polymer. Typicall 50µl of 1µM QDs in decane was diluted with 4.5ml 
cyclohexane and 0.5ml IGEPAL 520 was added. The 1mg HA-DOTA Cu polymer in 50 
µl water was then added to the solution and 50µl 0.1M TMAH in methanol was also 
added as a catalyst. The mixture was votexed for 1 min, and shaked for 60 min. After 
reaction, 1 ml ethanol was added and the solution was centrifuged at 6000g for 5 min to 
precipitate the HA polymer-coated QDs. The pellets were washed with additional ethanol 
for 3 times and washed with water once and finally re-dispersed in water. After 
centrifuging the QDs solution at 5000 g for 5 min to get rid of the undissolved parts, the 
supernatant which contains the HA polymer-coated QDs was purified using a 0.22 µm 
syringe filter. 
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For characterization, the UV-vis absorption spectrum was recorded on a UV-2550 
UV-vis spectrophotometer (Shimadzu). The fluorescence spectrum was recorded on a 
Nanolog FL3-2iHR (HORIBA JOBIN). The TEM was preformed on a JEM-2100F TEM 
machine. The Cu contents were estimated on an inductive coupled plasma-optical 
emission spectrometry (PROFILE SPEC, Leeman Labs, USA) by digesting QDs with 
HNO3 and perchloric acid. 
4.3.2 Results and Discussions 
Characterization of HA-cystamine-DOTA polymer 
The synthesis of HA-cysteamine-DOTA polymer involves three steps: synthesis 
of HA-cystamine polymer, DOTA conjugation to the HA-cystamine polymer and DTT 
reduction of the disulfide bond. 
For the HA-cystamine polymer conjugate DOTA, from the FT-IR image of HA-
cystamine-DOTA (Figure 4.24), the peak at 1730cm-1 which represents the C=O 
formation is a strong sign that DOTA was successfully conjugated to the HA backbone.  
 
Figure 4.24.  FT-IR image of HA and HA-cystamine-DOTA 
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The HA-cystamine conjugation was confirmed by NMR.  As shown in Figure 4.25, the 
comparison of HA and HA-cystamine-DOTA, the peak at around 2.85 ppm and 2.95 ppm 
which is the cystamine was shown, which proved successful conjugation of cystamine to 
HA polymer. Quantitative characterization of DOTA that was conjugated to HA-
cystamine polymer was also confirmed by NMR. The NMR curve was shown in Figure 
4.25, and the NMR prediction by chemdraw was shown in Figure 4.26. The circles of the 
same color represent the corresponded group. The amount of DOTA that was conjugated 
to HA can be calculated from the integration of the corresponding part on the NMR 
curve. After calculation, there were 1 DOTA on every 3 HA polymer.  
Characterization of HA-DOTA-Cu polymer coated QDs 
  UV-absorption and Fluorescence curve before and after HA-DOTA-Cu polymer 
coating were shown in Figure 4.27. The QDs absorption and emission curve after HA-
DOTA-Cu polymer coating keeps the same shape as before coating, thus indicates a good 
stability of the HA-DOTA-Cu polymer coated QDs. 
 
 




Figure 4.26. NMR prediction of HA-cystamine-DOTA by Chemdraw.  
 
 
Figure 4.27. UV-absorption and Fluorescence image of QDs and HA-Cu QDs  
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TEM results were shown in Figure 4.28. From the TEM, we can get the average 
size of the QDs was around 10 nm. The HA-DOTA Cu QDs distributed uniformly in 
size, which proves a well disperse in water. The surface conjugation of QDs with DOTA 
and further Cu ion chelation did not obviously affect the morphology of QDs, as 
evidenced by the TEM images. 
 
Figure 4.28. TEM figure of HA-DOTA Cu QDs to show a size distribution.  
 
Cu content determination of HA-DOTA Cu QDs by ICP-AES 
100 µl HA-DOTA Cu QDs were used for ICP-AES. Typically, 100 µl QDs were 
diluted with 5ml HNO3 and stay overnight. The second day 2 ml perchloric acid were 
added and the whole solution was heated to 170 °C for 1.5h. Finally, the solution was 
cooled to room temperature and pure water was added to 10ml for ICP-AES. After 
running ICP-AES, the Cu content in solution is 0.0571 µg/ml. therefore, there were total 
0.571µg Cu in 10ml solution. Namely, in 100µl QDs, the Cu content is 0.571 µg 
/(64g/mol) =0.0089 µmol = 8.9nmol.  
The concentration of Cu is 8.9nmol / 100µl=8.9*10-5 mol/L=89µM. The 
concentration of QDs was determined by UV-vis absorption, which is 74nM. Therefore, 




In this part, we have successfully conjugated HA-cysteamine polymer with 
DOTA via the formation of ester bonds between the carboxyl group in DOTA and the 
hydroxyl group in the HA backbone and the HA-cystamine DOTA polymer was used to 
coat NIR QDs. The resulting QDs have great water solubility and excellent colloidal 
stability. The QDs also has the binding ability of Cu through the DOTA group, and ICP-
AES results shows a relatively high amount of Cu content in the HA-DOTA Cu QDs. 
The preliminary results provide a future application for coupling 64Cu isotopes for PET 
imaging. Therefore, dual-modality PET/optical imaging probes can be realized through 
this novel method.  
4.4 Summary 
In this chapter, the Hyaluronic acid-cystamine polymer was conjugated with 
DTPA and DOTA for multi-modality MRI/optical and PET/optical imaging. The DTPA 
can conjugate Gd ion thus provides ability for MRI imaging and the calculated 
longitudinal relaxation rate is comparable with DTPA-Gd solution. The DOTA unit 
renders the QDs to have the ability for conjugating Cu ion, which provides future ability 
for 64Cu isotope coupling for PET imaging. The resulting QDs have great water 
solubility, and excellent colloidal stability and also show great biocompatibility and no 
significant toxicity to NIH/3T3 fibroblast cells and Hela cervical cancer cells. Moreover, 
the HA polymer-coated QDs hold CD44+ cancer cell targeting ability for cervical cancer 
cell lines. The HA-DTPA polymer can also conjugate 99mTc for SPECT imaging. 
Therefore, this novel HA-DTPA and HA-DOTA polymer holds the promise for multi-
modality imaging, such as MRI/optical, PET/optical, SPECT/optical and 
 90 
MRI/PET/SPECT/optical imaging and will have a significant impact on cancer 






 As a summary, we have successfully developed a novel HA-cysteamine polymer 
coated QDs, which are water-soluble, and stable for long time and over a large pH, range. 
The polymer coated QDs shows great biocompatibility and no significant toxicity. 
Moreover, the HA-cysteamine polymer coated QDs holds CD44+ cancer cell targeting 
ability for breast cancer cell lines. Based on this well-designed system, the Hyaluronic 
acid-cystamine polymer was further conjugated with DTPA and DOTA for multi-
modality MRI/optical and PET/optical imaging. The DTPA can conjugate Gd ion 
provides ability for MRI imaging and the calculated longitudinal relaxation rate is 
comparable with DTPA-Gd solution. The DOTA unit renders the QDs to have the ability 
for conjugating Cu ion, which provides future ability for 64Cu isotope coupling for PET 
imaging. The resulting QDs have great water solubility, and excellent colloidal stability 
and also show great biocompatibility and no significant toxicity to NIH/3T3 fibroblast 
cells and Hela cervical cancer cells. Moreover, the HA polymer-coated QDs hold CD44+ 
cancer cell targeting ability for cervical cancer Hela cell lines. The HA-DTPA polymer 
can also conjugate 99mTc for SPECT imaging. The QDs core can also be replaced with 
Au nanoparticles, which is suitable for CT enhancement imaging. Therefore, this novel 
HA-DTPA and HA-DOTA polymer holds the promise for multi-modality imaging, such 
as MRI/optical, MRI/CT, PET/optical, SPECT/optical and PET/CT/SPECT imaging. We 
expect this versatile method will have a significant impact on cancer diagnostics, 





Figure 5.1 Multi-modality imaging probe based on our HA-cystamine QDs system 
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